PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
8711744-6	1996	In CD-pretreated rats, CCl4-induced toxicity progressed with time culminating in 25 and 100% mortality by 72 h after CCl4 in 45- and 60-day rats, respectively, in contrast to regression of CCl4-induced toxicity and 0% mortality in 20-day rats.	Chlordecone	3-5	C-C motif chemokine ligand 4	Rattus norvegicus	23-27
8952712-1	1996	Chlordecone (Kepone) is a polychlorinated hydrocarbon that has a low affinity for the estrogen receptor.	Chlordecone	0-11	estrogen receptor 1	Rattus norvegicus	86-103
8952712-1	1996	Chlordecone (Kepone) is a polychlorinated hydrocarbon that has a low affinity for the estrogen receptor.	Chlordecone	13-19	estrogen receptor 1	Rattus norvegicus	86-103
8711744-6	1996	In CD-pretreated rats, CCl4-induced toxicity progressed with time culminating in 25 and 100% mortality by 72 h after CCl4 in 45- and 60-day rats, respectively, in contrast to regression of CCl4-induced toxicity and 0% mortality in 20-day rats.	Chlordecone	3-5	C-C motif chemokine ligand 4	Rattus norvegicus	117-121
8711744-6	1996	In CD-pretreated rats, CCl4-induced toxicity progressed with time culminating in 25 and 100% mortality by 72 h after CCl4 in 45- and 60-day rats, respectively, in contrast to regression of CCl4-induced toxicity and 0% mortality in 20-day rats.	Chlordecone	3-5	C-C motif chemokine ligand 4	Rattus norvegicus	117-121
8621113-6	1996	The integration of these two repair processes as shown through experimental manipulation provides a new mechanistic framework to account for the previously reported profound (67-fold) potentiation of acute CCl4 hepatotoxicity by chlordecone (kepone) in adult male Sprague-Dawley rats as well as important interspecies variation in susceptibility to hepatotoxic agents in general and CCl4 in particular.	Chlordecone	229-240	C-C motif chemokine ligand 4	Rattus norvegicus	206-210
8621113-6	1996	The integration of these two repair processes as shown through experimental manipulation provides a new mechanistic framework to account for the previously reported profound (67-fold) potentiation of acute CCl4 hepatotoxicity by chlordecone (kepone) in adult male Sprague-Dawley rats as well as important interspecies variation in susceptibility to hepatotoxic agents in general and CCl4 in particular.	Chlordecone	229-240	C-C motif chemokine ligand 4	Rattus norvegicus	383-387
8621113-6	1996	The integration of these two repair processes as shown through experimental manipulation provides a new mechanistic framework to account for the previously reported profound (67-fold) potentiation of acute CCl4 hepatotoxicity by chlordecone (kepone) in adult male Sprague-Dawley rats as well as important interspecies variation in susceptibility to hepatotoxic agents in general and CCl4 in particular.	Chlordecone	242-248	C-C motif chemokine ligand 4	Rattus norvegicus	206-210
8621113-6	1996	The integration of these two repair processes as shown through experimental manipulation provides a new mechanistic framework to account for the previously reported profound (67-fold) potentiation of acute CCl4 hepatotoxicity by chlordecone (kepone) in adult male Sprague-Dawley rats as well as important interspecies variation in susceptibility to hepatotoxic agents in general and CCl4 in particular.	Chlordecone	242-248	C-C motif chemokine ligand 4	Rattus norvegicus	383-387
8571362-4	1995	Chlordecone-potentiated halomethane hepatotoxicity, where suppression of cell division and tissue repair response permits very high amplification of CCl4 injury culminating in animal mortality, is one such model.	Chlordecone	0-11	C-C motif chemokine ligand 4	Homo sapiens	149-153
8896716-1	1996	Carbon tetrachloride (CCl4) lethality in Sprague-Dawley rats is greatly amplified by pretreatment of Kepone (decachlorooctahydro-1,3,2-metheno-2H-cyclobuta[cd] pentalen-2-one).	Chlordecone	101-107	C-C motif chemokine ligand 4	Rattus norvegicus	22-26
8896716-4	1996	Based on the available mechanistic information on Kepone/CCl4 interaction, a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model was constructed where the following effects of Kepone on CCl4 toxicity are incorporated: (1) inhibition of mitosis; (2) reduction of repair mechanism of hepatocellular injury; (3) suppression of phagocytosis.	Chlordecone	194-200	C-C motif chemokine ligand 4	Rattus norvegicus	57-61
8896716-4	1996	Based on the available mechanistic information on Kepone/CCl4 interaction, a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model was constructed where the following effects of Kepone on CCl4 toxicity are incorporated: (1) inhibition of mitosis; (2) reduction of repair mechanism of hepatocellular injury; (3) suppression of phagocytosis.	Chlordecone	194-200	C-C motif chemokine ligand 4	Rattus norvegicus	204-208
8896716-16	1996	Our modeling and experimental results verified the earlier findings of Mehendale (1990) for the 67-fold amplification of CCl4 lethality in the presence of Kepone.	Chlordecone	155-161	C-C motif chemokine ligand 4	Rattus norvegicus	121-125
8896716-17	1996	However, much of this amplification of CCl4 lethality with Kepone pretreatment was probably due to pharmacokinetic factors, because when target tissue dose (i.e., model estimated amount of CCl4 metabolites) was used to evaluate lethality, this amplification was reduced to 4-fold.	Chlordecone	59-65	C-C motif chemokine ligand 4	Rattus norvegicus	39-43
8896716-17	1996	However, much of this amplification of CCl4 lethality with Kepone pretreatment was probably due to pharmacokinetic factors, because when target tissue dose (i.e., model estimated amount of CCl4 metabolites) was used to evaluate lethality, this amplification was reduced to 4-fold.	Chlordecone	59-65	C-C motif chemokine ligand 4	Rattus norvegicus	189-193
8571364-9	1995	In this presentation, one of our specific research projects is described: PB-PK/PD modeling of toxicologic interactions between Kepone and carbon tetrachloride (CCl4) and the coupling of Monte Carlo simulation for the prediction of acute toxicity.	Chlordecone	128-134	C-C motif chemokine ligand 4	Homo sapiens	161-165
7478807-1	1995	Previous studies revealed that postnatally developing rats are resilient to the lethal effects of chlordecone (CD) + carbon tetrachloride (CCl4) combination.	Chlordecone	98-109	C-C motif chemokine ligand 4	Rattus norvegicus	139-143
8847708-1	1995	The resiliency of rats during early post-natal development to CCl4 or to an interactive hepatotoxicity of chlordecone (CD) + CCl4 has been shown to be due to an efficient stimulation of tissue repair.	Chlordecone	106-117	C-C motif chemokine ligand 4	Rattus norvegicus	125-129
8800639-2	1995	We showed that chlordecone, nonylphenol, a polychlorobiphenol (PCB) mixture (Aroclor 1245) and lindane were able to induce ER and Vg mRNA accumulation.	Chlordecone	15-26	estrogen receptor	Oncorhynchus mykiss	123-125
8800639-2	1995	We showed that chlordecone, nonylphenol, a polychlorobiphenol (PCB) mixture (Aroclor 1245) and lindane were able to induce ER and Vg mRNA accumulation.	Chlordecone	15-26	LOC100136735	Oncorhynchus mykiss	130-132
8800639-4	1995	Among these four xenobiotics, only chlordecone and nonylphenol were able to displace the binding of [3H]estradiol to ER-enriched COS-1 extracts, and to activate an estrogen-dependent reporter gene (ERE-TK-CAT) cotransfected with an expression vector containing ER cDNA.	Chlordecone	35-46	estrogen receptor	Oncorhynchus mykiss	117-119
8800639-4	1995	Among these four xenobiotics, only chlordecone and nonylphenol were able to displace the binding of [3H]estradiol to ER-enriched COS-1 extracts, and to activate an estrogen-dependent reporter gene (ERE-TK-CAT) cotransfected with an expression vector containing ER cDNA.	Chlordecone	35-46	estrogen receptor	Oncorhynchus mykiss	198-200
8800639-5	1995	The results suggest that chlordecone and nonylphenol are direct inducers of rainbow trout ER and Vg gene expression, whereas PCBs and lindane act through their hepatic metabolites.	Chlordecone	25-36	estrogen receptor	Oncorhynchus mykiss	90-92
8800639-5	1995	The results suggest that chlordecone and nonylphenol are direct inducers of rainbow trout ER and Vg gene expression, whereas PCBs and lindane act through their hepatic metabolites.	Chlordecone	25-36	LOC100136735	Oncorhynchus mykiss	97-99
7478807-7	1995	In CD+CCl4 treatment, ALT, SDH, and bilirubin levels peaked between 36 and 48 h after CCl4.	Chlordecone	3-5	C-C motif chemokine ligand 4	Rattus norvegicus	86-90
7478807-9	1995	CD-potentiated hepatotoxicity and lethality of CCl4 begin to be manifested in 45-d-old rats at 48 h and later times (25% mortality), whereas adult rats experience progressive hepatotoxic injury and 100% mortality by 72 h. In contrast, regardless of pretreatment, 20-d-old rats recover fully from injury by 72 h after CCl4 treatment.	Chlordecone	0-2	C-C motif chemokine ligand 4	Rattus norvegicus	47-51
7478807-9	1995	CD-potentiated hepatotoxicity and lethality of CCl4 begin to be manifested in 45-d-old rats at 48 h and later times (25% mortality), whereas adult rats experience progressive hepatotoxic injury and 100% mortality by 72 h. In contrast, regardless of pretreatment, 20-d-old rats recover fully from injury by 72 h after CCl4 treatment.	Chlordecone	0-2	C-C motif chemokine ligand 4	Rattus norvegicus	317-321
7504640-1	1993	Chlordecone (Kepone) amplification of CCl4 toxicity occurs at small, nontoxic levels of chlordecone and CCl4 and results in highly increased irreversible hepatotoxicity culminating in lethality.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	38-42
7513451-0	1994	Regulation of cytochrome P450 2B1/2 mRNAs by Kepone (chlordecone) and potent estrogens in primary cultures of adult rat hepatocytes on Matrigel.	Chlordecone	45-51	cytochrome P450, family 2, subfamily b, polypeptide 12	Rattus norvegicus	14-35
7513451-0	1994	Regulation of cytochrome P450 2B1/2 mRNAs by Kepone (chlordecone) and potent estrogens in primary cultures of adult rat hepatocytes on Matrigel.	Chlordecone	53-64	cytochrome P450, family 2, subfamily b, polypeptide 12	Rattus norvegicus	14-35
7513451-5	1994	Indeed, Kepone treatment actively suppressed induction of 2B1 and 2B2 mRNAs in hepatocytes cotreated with phenobarbital.	Chlordecone	8-14	UDP glucuronosyltransferase family 2 member B17	Rattus norvegicus	58-69
7513451-12	1994	Treatment with chloral hydrate (3 x 10(-3) M), like Kepone (10(-5) M), suppressed 2B1/2 mRNA induction following phenobarbital (10(-4) M) treatment, while Kepone alcohol (10(-5) M), which is not a gem-diol, produced less suppression.	Chlordecone	52-58	UDP glucuronosyltransferase family 2 member B17	Rattus norvegicus	82-85
7513451-13	1994	Our results suggest that selective induction by Kepone of 2B2 is unlikely related to its effects as a weak classical estrogen, while the ability of Kepone to suppress induction of 2B1 and 2B2 by PB may be related to its properties as a gem-diol.	Chlordecone	148-154	UDP glucuronosyltransferase family 2 member B17	Rattus norvegicus	180-183
7516359-0	1994	Adenosine triphosphate protection of chlordecone-amplified CCl4 hepatotoxicity and lethality.	Chlordecone	37-48	C-C motif chemokine ligand 4	Rattus norvegicus	59-63
7516359-1	1994	Dietary exposure to a nontoxic level of chlordecone (10 ppm for 15 days) followed by a single exposure to a subtoxic dose of CCl4 (100 microliters/kg, ip) is known to result in a 67-fold amplification of CCl4 toxicity.	Chlordecone	40-51	C-C motif chemokine ligand 4	Rattus norvegicus	204-208
7516359-5	1994	Without ATP administration all rats died within 72 h, while administration of ATP (100 mg/rat, sc) to chlordecone-pretreated rats at -1, +1, 3, 5, 12, 24 and 36 h of CCl4 injection resulted in 100% survival.	Chlordecone	102-113	C-C motif chemokine ligand 4	Rattus norvegicus	166-170
7516359-6	1994	Injection of ATP, at -1, +1, 3 and 5 h of CCl4 administration to chlordecone pretreated rats decreased plasma enzyme elevations (alanine and aspartate aminotransferase, sorbitol dehydrogenase) as well as substantially preventing elevation of plasma bilirubin levels at 6, 12 and 24 h. Hepatic ATP levels were also elevated at 6 and 12 h, but not at 24 h.(ABSTRACT TRUNCATED AT 250 WORDS)	Chlordecone	65-76	C-C motif chemokine ligand 4	Rattus norvegicus	42-46
7516359-6	1994	Injection of ATP, at -1, +1, 3 and 5 h of CCl4 administration to chlordecone pretreated rats decreased plasma enzyme elevations (alanine and aspartate aminotransferase, sorbitol dehydrogenase) as well as substantially preventing elevation of plasma bilirubin levels at 6, 12 and 24 h. Hepatic ATP levels were also elevated at 6 and 12 h, but not at 24 h.(ABSTRACT TRUNCATED AT 250 WORDS)	Chlordecone	65-76	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	141-167
7516359-6	1994	Injection of ATP, at -1, +1, 3 and 5 h of CCl4 administration to chlordecone pretreated rats decreased plasma enzyme elevations (alanine and aspartate aminotransferase, sorbitol dehydrogenase) as well as substantially preventing elevation of plasma bilirubin levels at 6, 12 and 24 h. Hepatic ATP levels were also elevated at 6 and 12 h, but not at 24 h.(ABSTRACT TRUNCATED AT 250 WORDS)	Chlordecone	65-76	sorbitol dehydrogenase	Rattus norvegicus	169-191
7535226-3	1994	Dietary exposure to a nontoxic dose of chlordecone (CD; 10 ppm, 15 days) results in a 67-fold increase in lethality of an ordinarily inconsequential dose of CCl4 (100 microliters/kg, ip).	Chlordecone	39-50	C-C motif chemokine ligand 4	Rattus norvegicus	157-161
7535226-3	1994	Dietary exposure to a nontoxic dose of chlordecone (CD; 10 ppm, 15 days) results in a 67-fold increase in lethality of an ordinarily inconsequential dose of CCl4 (100 microliters/kg, ip).	Chlordecone	52-54	C-C motif chemokine ligand 4	Rattus norvegicus	157-161
7504640-1	1993	Chlordecone (Kepone) amplification of CCl4 toxicity occurs at small, nontoxic levels of chlordecone and CCl4 and results in highly increased irreversible hepatotoxicity culminating in lethality.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	104-108
7504640-1	1993	Chlordecone (Kepone) amplification of CCl4 toxicity occurs at small, nontoxic levels of chlordecone and CCl4 and results in highly increased irreversible hepatotoxicity culminating in lethality.	Chlordecone	13-19	C-C motif chemokine ligand 4	Rattus norvegicus	38-42
7504640-1	1993	Chlordecone (Kepone) amplification of CCl4 toxicity occurs at small, nontoxic levels of chlordecone and CCl4 and results in highly increased irreversible hepatotoxicity culminating in lethality.	Chlordecone	13-19	C-C motif chemokine ligand 4	Rattus norvegicus	104-108
7504640-1	1993	Chlordecone (Kepone) amplification of CCl4 toxicity occurs at small, nontoxic levels of chlordecone and CCl4 and results in highly increased irreversible hepatotoxicity culminating in lethality.	Chlordecone	88-99	C-C motif chemokine ligand 4	Rattus norvegicus	38-42
7504640-3	1993	The present studies were designed to evaluate whether hepatic failure is the cause of the lethality during chlordecone-amplified CCl4 toxicity.	Chlordecone	107-118	C-C motif chemokine ligand 4	Rattus norvegicus	129-133
7504640-8	1993	As expected CCl4 administration to chlordecone-pretreated rats resulted in 20% lethality by 36 hr, which progressed with time, and all rats died within 72 hr.	Chlordecone	35-46	C-C motif chemokine ligand 4	Rattus norvegicus	12-16
7690997-1	1993	Earlier work has shown increased hepatocellular free Ca2+ levels in rats receiving a single subtoxic dose of CCl4 after dietary pretreatment with nontoxic (10 ppm, 15 days) levels of chlordecone (CD), indicating a significant perturbation of Ca2+ homeostasis in the interactive toxicity of CD + CCl4 combination treatment.	Chlordecone	183-194	C-C motif chemokine ligand 4	Rattus norvegicus	109-113
7690997-1	1993	Earlier work has shown increased hepatocellular free Ca2+ levels in rats receiving a single subtoxic dose of CCl4 after dietary pretreatment with nontoxic (10 ppm, 15 days) levels of chlordecone (CD), indicating a significant perturbation of Ca2+ homeostasis in the interactive toxicity of CD + CCl4 combination treatment.	Chlordecone	196-198	C-C motif chemokine ligand 4	Rattus norvegicus	109-113
7690997-11	1993	CCl4 administration to both normal and CD-pretreated rats resulted in significant inhibition of microsomal and mitochondrial 45Ca uptake as early as 1 hr at all concentrations of free calcium.	Chlordecone	39-41	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
7687794-3	1993	33, 289-299, 1990) indicate that prior exposure to chlordecone markedly enhances CCl4-induced lethality.	Chlordecone	51-62	C-C motif chemokine ligand 4	Rattus norvegicus	81-85
7687794-4	1993	It was established that chlordecone suppressed the capacity of CCl4-induced toxicity to cause an early (i.e., 6 hr after exposure) hepatocellular division which is believed to be a critical tissue response reducing subsequent CCl4-induced hepatotoxicity.	Chlordecone	24-35	C-C motif chemokine ligand 4	Rattus norvegicus	63-67
7687794-4	1993	It was established that chlordecone suppressed the capacity of CCl4-induced toxicity to cause an early (i.e., 6 hr after exposure) hepatocellular division which is believed to be a critical tissue response reducing subsequent CCl4-induced hepatotoxicity.	Chlordecone	24-35	C-C motif chemokine ligand 4	Rattus norvegicus	226-230
7681558-2	1993	The well-documented amplification of CCl4 (100 microL/kg) hepatotoxicity and lethality by prior dietary exposure to chlordecone (10 ppm, for 15 d) was absent in neonatal and developing rats through 35 d of age.	Chlordecone	116-127	C-C motif chemokine ligand 4	Rattus norvegicus	37-41
7681558-3	1993	The chlordecone-potentiated hepatotoxicity and lethality of CCl4 was partially expressed in 45-d-old rats and fully expressed in 60-d-old rats.	Chlordecone	4-15	C-C motif chemokine ligand 4	Rattus norvegicus	60-64
1284994-0	1992	Pivotal role of hepatocellular regeneration in the ultimate hepatotoxicity of CCl4 in chlordecone-, mirex-, or phenobarbital-pretreated rats.	Chlordecone	86-97	C-C motif chemokine ligand 4	Rattus norvegicus	78-82
1284994-1	1992	Our earlier histomorphometric and biochemical studies suggested that the progressive phase of the interactive toxicity of chlordecone (CD) + CCl4 involves suppression of hepatocellular regeneration.	Chlordecone	122-133	C-C motif chemokine ligand 4	Rattus norvegicus	141-145
1284994-6	1992	Dietary 10 ppm CD potentiated the hepatotoxicity of CCl4 to a greater extent than PB or M, as evidenced by elevations in plasma enzymes.	Chlordecone	15-17	C-C motif chemokine ligand 4	Rattus norvegicus	52-56
1284994-9	1992	Actual liver injury by CCl4 was greater in PB- than in CD-pretreated rats, as evidenced by histopathological observations.	Chlordecone	55-57	C-C motif chemokine ligand 4	Rattus norvegicus	23-27
1284994-10	1992	A 100% mortality occurred in CD-pretreated rats at 60 hr after CCl4 administration, whereas no mortality occurred in either N-, M-, or PB-pretreated rats, indicating recovery from liver injury.	Chlordecone	29-31	C-C motif chemokine ligand 4	Rattus norvegicus	63-67
1284994-11	1992	Hepatocellular nuclear DNA levels were significantly decreased starting at 6 hr after CCl4 administration to CD-pretreated rats, but not in M- or PB-pretreated rats.	Chlordecone	109-111	C-C motif chemokine ligand 4	Rattus norvegicus	86-90
1715015-6	1991	However, in the same kepone-treated cells, P450b mRNA or P450b immunoreactive protein was induced only slightly, if at all.	Chlordecone	21-27	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	57-62
1717700-0	1991	Combined effects of carbon tetrachloride and chlordecone on calmodulin activity in gerbil brain.	Chlordecone	45-56	calmodulin 1	Homo sapiens	60-70
1717700-1	1991	The potentiation of carbon tetrachloride (CCl4) toxicity by chlordecone (CD) pretreatment in different animal models is well established.	Chlordecone	60-71	C-C motif chemokine ligand 4	Homo sapiens	42-46
1717700-1	1991	The potentiation of carbon tetrachloride (CCl4) toxicity by chlordecone (CD) pretreatment in different animal models is well established.	Chlordecone	73-75	C-C motif chemokine ligand 4	Homo sapiens	42-46
1717700-3	1991	The present study was initiated to determine whether CD preexposure potentiates CCl4 neurotoxicity in gerbils.	Chlordecone	53-55	C-C motif chemokine ligand 4	Homo sapiens	80-84
1717700-7	1991	Ca(2+)-ATPase and CaM activities were decreased at 0.5 and 2 h in both CD-preexposed and CCl4-treated gerbils.	Chlordecone	71-73	calmodulin 1	Homo sapiens	18-21
1715015-0	1991	Selective induction of cytochrome P450e by kepone (chlordecone) in primary cultures of adult rat hepatocytes.	Chlordecone	43-49	cytochrome P450, family 2, subfamily b, polypeptide 2	Rattus norvegicus	23-39
1715015-8	1991	Selective induction of P450e by kepone in the hepatocyte cultures, the first pharmacologic dissociation of the induction of P450b and P450e mRNAs and proteins, was not apparent in kepone-treated rats, where both P450b and P450e mRNAs were increased to equivalent extents.	Chlordecone	32-38	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	124-139
1715015-0	1991	Selective induction of cytochrome P450e by kepone (chlordecone) in primary cultures of adult rat hepatocytes.	Chlordecone	51-62	cytochrome P450, family 2, subfamily b, polypeptide 2	Rattus norvegicus	23-39
1715015-8	1991	Selective induction of P450e by kepone in the hepatocyte cultures, the first pharmacologic dissociation of the induction of P450b and P450e mRNAs and proteins, was not apparent in kepone-treated rats, where both P450b and P450e mRNAs were increased to equivalent extents.	Chlordecone	32-38	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	124-129
1714637-11	1991	Results of previous studies had led to the suggestion that chlordecone"s inhibition of sexual behaviors resulted from its interaction with the intracellular estrogen receptor.	Chlordecone	59-70	estrogen receptor 1	Rattus norvegicus	157-174
1715015-5	1991	Kepone also resembled phenobarbital in these experiments, in that there were dose-dependent increases in the amounts of hepatocellular P450p, P450pcn2, P450PB-1, P450f, and NADPH-cytochrome P450 oxidoreductase mRNAs.	Chlordecone	0-6	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	142-150
1715015-5	1991	Kepone also resembled phenobarbital in these experiments, in that there were dose-dependent increases in the amounts of hepatocellular P450p, P450pcn2, P450PB-1, P450f, and NADPH-cytochrome P450 oxidoreductase mRNAs.	Chlordecone	0-6	cytochrome P450, family 2, subfamily c, polypeptide 12	Rattus norvegicus	152-160
1715015-5	1991	Kepone also resembled phenobarbital in these experiments, in that there were dose-dependent increases in the amounts of hepatocellular P450p, P450pcn2, P450PB-1, P450f, and NADPH-cytochrome P450 oxidoreductase mRNAs.	Chlordecone	0-6	cytochrome P450, family 2, subfamily c, polypeptide 7	Rattus norvegicus	162-167
1715015-6	1991	However, in the same kepone-treated cells, P450b mRNA or P450b immunoreactive protein was induced only slightly, if at all.	Chlordecone	21-27	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	43-48
1706539-19	1991	However, CCl4 challenge to rats maintained on CD resulted in progressive injury, characterized by the appearance of ballooned cells, necrotic cells, and cells with lipid droplets in the liver.	Chlordecone	46-48	C-C motif chemokine ligand 4	Rattus norvegicus	9-13
1706539-1	1991	Chlordecone (CD) pretreatment is well known to greatly potentiate CCl4 toxicity.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	66-70
1717217-5	1991	A cumulative dose of 45 mg/kg CD caused a PDR, increased the content of cytochrome P-450, and elevated the activities of ethoxyresorufin- and ethoxycoumarin-O-deethylases (EROD and ECOD).	Chlordecone	30-32	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	72-88
1706539-1	1991	Chlordecone (CD) pretreatment is well known to greatly potentiate CCl4 toxicity.	Chlordecone	13-15	C-C motif chemokine ligand 4	Rattus norvegicus	66-70
1706540-1	1991	Previous work has shown that chlordecone (CD)-amplified CCl4 hepatotoxicity and lethality can be mitigated by pretreatment with cyanidanol.	Chlordecone	29-40	C-C motif chemokine ligand 4	Rattus norvegicus	56-60
1706539-10	1991	Without cyanidanol, CD + CCl4 combination caused 50 and 100% lethality after CCl4 (L) and the standard dose, respectively, while the same doses of CCl4 alone did not cause lethal effects.	Chlordecone	20-22	C-C motif chemokine ligand 4	Rattus norvegicus	77-81
1706539-10	1991	Without cyanidanol, CD + CCl4 combination caused 50 and 100% lethality after CCl4 (L) and the standard dose, respectively, while the same doses of CCl4 alone did not cause lethal effects.	Chlordecone	20-22	C-C motif chemokine ligand 4	Rattus norvegicus	77-81
1706539-12	1991	The combination of CD + standard dose of CCl4 resulted in progressive and marked elevations of all three serum enzymes at all time intervals until the death of animals.	Chlordecone	19-23	C-C motif chemokine ligand 4	Rattus norvegicus	41-45
1706540-1	1991	Previous work has shown that chlordecone (CD)-amplified CCl4 hepatotoxicity and lethality can be mitigated by pretreatment with cyanidanol.	Chlordecone	42-44	C-C motif chemokine ligand 4	Rattus norvegicus	56-60
1706540-2	1991	These studies also revealed that stimulated hepatocellular regeneration might play an important role in the cyanidanol protection of CD-amplified CCl4 toxicity.	Chlordecone	133-135	C-C motif chemokine ligand 4	Rattus norvegicus	146-150
1706540-10	1991	Challenge by the same dose of CCl4 (100 microliters/kg) to CD-pretreated rats not protected by cyanidanol failed to cause any increase in [3H]thymidine incorporation up to 36 hr and resulted in animal death starting at 36 hr.	Chlordecone	59-61	C-C motif chemokine ligand 4	Rattus norvegicus	30-34
1704867-0	1991	Carbon tetrachloride-induced alterations of hepatic calmodulin and free calcium levels in rats pretreated with chlordecone.	Chlordecone	111-122	calmodulin 1	Rattus norvegicus	52-62
1705986-0	1991	Amplification of CCl4 toxicity by chlordecone: destruction of rat hepatic microsomal cytochrome P-450 subpopulation.	Chlordecone	34-45	C-C motif chemokine ligand 4	Rattus norvegicus	17-21
1705986-0	1991	Amplification of CCl4 toxicity by chlordecone: destruction of rat hepatic microsomal cytochrome P-450 subpopulation.	Chlordecone	34-45	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	85-101
1705986-1	1991	Previous work has established marked amplification of CCl4 hepatotoxicity by prior exposure to chlordecone (CD).	Chlordecone	95-106	C-C motif chemokine ligand 4	Rattus norvegicus	54-58
1705986-1	1991	Previous work has established marked amplification of CCl4 hepatotoxicity by prior exposure to chlordecone (CD).	Chlordecone	108-110	C-C motif chemokine ligand 4	Rattus norvegicus	54-58
1705986-15	1991	In CD + CCl4 treatment, absence of peaks II and III was noted.	Chlordecone	3-7	C-C motif chemokine ligand 4	Rattus norvegicus	8-12
1705986-17	1991	These findings suggest that (1) CoCl2 does not selectively decrease or spare any P-450 isozymes and (2) CD + CCl4 interaction does destroy specific P-450 isozymes.	Chlordecone	104-108	C-C motif chemokine ligand 4	Rattus norvegicus	109-113
1704867-2	1991	Previous studies from our laboratory indicated excessive accumulation of Ca2+ in hepatocytes succeeded by rapid glycogen breakdown and suppressed cell division in rats receiving CCl4 after previous dietary exposure to 10 ppm chlordecone.	Chlordecone	225-236	C-C motif chemokine ligand 4	Rattus norvegicus	178-182
1704867-3	1991	Since calmodulin plays a major role in Ca2(+)-regulated events and has been reported to be localized in mitotic apparatus during cell division, we have assessed subcellular distribution of calmodulin and estimated cytosolic phosphorylase a to indicate cytosolic free Ca2+ levels in livers of rats fed 0 ppm or 10 ppm (chlordecone) in the diet for 15 days before CCl4 (100 microliters/kg) administration to understand the role of Ca2(+)-calmodulin in chlordecone + CCl4 toxicity.	Chlordecone	318-329	calmodulin 1	Rattus norvegicus	6-16
1704867-3	1991	Since calmodulin plays a major role in Ca2(+)-regulated events and has been reported to be localized in mitotic apparatus during cell division, we have assessed subcellular distribution of calmodulin and estimated cytosolic phosphorylase a to indicate cytosolic free Ca2+ levels in livers of rats fed 0 ppm or 10 ppm (chlordecone) in the diet for 15 days before CCl4 (100 microliters/kg) administration to understand the role of Ca2(+)-calmodulin in chlordecone + CCl4 toxicity.	Chlordecone	450-461	calmodulin 1	Rattus norvegicus	6-16
1704867-6	1991	However, serum AST and ALT elevations were severalfold higher, and progressive increase was observed starting 4 hr after CCl4 administration to chlordecone rats.	Chlordecone	144-155	C-C motif chemokine ligand 4	Rattus norvegicus	121-125
1704867-9	1991	However, the CCl4 hepatotoxicity is progressive in chlordecone rats without recovery.	Chlordecone	51-62	C-C motif chemokine ligand 4	Rattus norvegicus	13-17
1696822-0	1990	Altered hepatic energy status in chlordecone (Kepone)-potentiated CCl4 hepatotoxicity.	Chlordecone	33-44	C-C motif chemokine ligand 4	Rattus norvegicus	66-70
1708849-3	1990	One such model is available, where prior exposure to nontoxic levels of the pesticide Kepone (chlordecone) results in a 67-fold amplication of CCl4 lethality in rats.	Chlordecone	86-92	C-C motif chemokine ligand 4	Rattus norvegicus	143-147
1708849-3	1990	One such model is available, where prior exposure to nontoxic levels of the pesticide Kepone (chlordecone) results in a 67-fold amplication of CCl4 lethality in rats.	Chlordecone	94-105	C-C motif chemokine ligand 4	Rattus norvegicus	143-147
1708849-5	1990	This propensity for chlordecone to potentiate hepatotoxicity of halomethanes such as CCl4, CHCl3, and BrCCl3 has been a subject of intense study to unravel the underlying mechanism.	Chlordecone	20-31	C-C motif chemokine ligand 4	Rattus norvegicus	85-89
1696822-0	1990	Altered hepatic energy status in chlordecone (Kepone)-potentiated CCl4 hepatotoxicity.	Chlordecone	46-52	C-C motif chemokine ligand 4	Rattus norvegicus	66-70
1696822-1	1990	Previous studies have demonstrated that increased intracellular calcium, depletion of glycogen, and suppressed hepatocellular division resulting in progression of hepatic lesion without recovery are associated with chlordecone (CD)-potentiated CCl4 hepatotoxicity.	Chlordecone	215-226	C-C motif chemokine ligand 4	Rattus norvegicus	244-248
1696822-1	1990	Previous studies have demonstrated that increased intracellular calcium, depletion of glycogen, and suppressed hepatocellular division resulting in progression of hepatic lesion without recovery are associated with chlordecone (CD)-potentiated CCl4 hepatotoxicity.	Chlordecone	228-230	C-C motif chemokine ligand 4	Rattus norvegicus	244-248
1696822-5	1990	However, CCl4 administration to CD pretreated rats resulted in significantly decreased hepatic ATP content as early as 1 hr (36%), and this decrease was irreversibly progressive with time (81% at 6 hr).	Chlordecone	32-34	C-C motif chemokine ligand 4	Rattus norvegicus	9-13
1696822-8	1990	These findings indicate that CCl4 administration to CD but not to PB or mirex pretreated rats results in a severely compromised energy status of the liver.	Chlordecone	52-54	C-C motif chemokine ligand 4	Rattus norvegicus	29-33
1696822-9	1990	The progressive and early depletion of liver ATP and the inhibition of Mg2(+)-ATPase in CD + CCl4 treated rats indicate the association of compromised energy status with altered Ca2+ homeostasis, depletion of glycogen, and suppressed cell division in CD-potentiated CCl4 toxicity.	Chlordecone	88-92	C-C motif chemokine ligand 4	Rattus norvegicus	93-97
1698228-1	1990	The mechanism by which chlordecone (CD) amplifies the hepatotoxicity of halomethanes such as CCl4, CHCl3, and BrCCl3 has been a subject of intense study.	Chlordecone	23-34	C-C motif chemokine ligand 4	Rattus norvegicus	93-97
1696756-0	1990	Lethal effects of CCl4 and its metabolism by Mongolian gerbils pretreated with chlordecone, phenobarbital, or mirex.	Chlordecone	79-90	C-C motif chemokine ligand 4	Rattus norvegicus	18-22
1696756-2	1990	On the other hand, gerbils are refractory to chlordecone (CD) potentiation of CCl4 toxicity.	Chlordecone	45-56	C-C motif chemokine ligand 4	Rattus norvegicus	78-82
1696756-2	1990	On the other hand, gerbils are refractory to chlordecone (CD) potentiation of CCl4 toxicity.	Chlordecone	58-60	C-C motif chemokine ligand 4	Rattus norvegicus	78-82
1696756-3	1990	To investigate the possible mechanism underlying the high sensitivity of gerbils to CCl4 lethality, the metabolism of CCl4 was studied in gerbils pretreated with dietary CD, phenobarbital (PB), or mirex (M) at 10, 225, and 10 ppm, respectively.	Chlordecone	170-172	C-C motif chemokine ligand 4	Rattus norvegicus	118-122
1696756-13	1990	However, the enhanced metabolism of CCl4 found in CD-, PB-, or M-pretreated gerbils did not lead to amplified hepatotoxic and lethal effects of CCl4.	Chlordecone	50-52	C-C motif chemokine ligand 4	Rattus norvegicus	36-40
1698228-1	1990	The mechanism by which chlordecone (CD) amplifies the hepatotoxicity of halomethanes such as CCl4, CHCl3, and BrCCl3 has been a subject of intense study.	Chlordecone	36-38	C-C motif chemokine ligand 4	Rattus norvegicus	93-97
1692334-0	1990	Chlordecone interaction of calmodulin binding with phosphodiesterase.	Chlordecone	0-11	calmodulin 1	Homo sapiens	27-37
1692334-9	1990	Chlordecone significantly decreased (P less than 0.05) CaM-activated PDE in a concentration-dependent manner without affecting the basal enzyme.	Chlordecone	0-11	calmodulin 1	Homo sapiens	55-58
1692334-10	1990	Combination of chlordecone with W-7 (CaM antagonist) increased the inhibitory effect of W-7 on CaM activity.	Chlordecone	15-26	calmodulin 1	Homo sapiens	37-40
1692334-10	1990	Combination of chlordecone with W-7 (CaM antagonist) increased the inhibitory effect of W-7 on CaM activity.	Chlordecone	15-26	calmodulin 1	Homo sapiens	95-98
1692334-14	1990	compounds tested, chlordecone is a specific inhibitor of CaM-activated PDE.	Chlordecone	18-29	calmodulin 1	Homo sapiens	57-60
2480256-0	1989	Protection from chlordecone (Kepone)-potentiated CCl4 hepatotoxicity in rats by fructose 1,6-diphosphate.	Chlordecone	16-27	C-C motif chemokine ligand 4	Rattus norvegicus	49-53
2481348-3	1989	We developed such a model where prior exposure to non-toxic levels of the pesticide Kepone (chlordecone) results in a 67-fold amplification of CCl4 lethality in experimental animals.	Chlordecone	84-90	C-C motif chemokine ligand 4	Homo sapiens	143-147
2481348-3	1989	We developed such a model where prior exposure to non-toxic levels of the pesticide Kepone (chlordecone) results in a 67-fold amplification of CCl4 lethality in experimental animals.	Chlordecone	92-103	C-C motif chemokine ligand 4	Homo sapiens	143-147
2481348-4	1989	The mechanism(s) by which chlordecone amplifies the hepatotoxicity of halomethanes such as CCl4, CHCl3, and BrCCl3 has been a subject of intense study.	Chlordecone	26-37	C-C motif chemokine ligand 4	Homo sapiens	91-95
2481348-10	1989	Such regeneration and hepatic tissue repair processes are totally suppressed in animals exposed to chlordecone prior to CCl4.	Chlordecone	99-110	C-C motif chemokine ligand 4	Homo sapiens	120-124
2481348-11	1989	Thus, the arrested hepatocellular repair and renovation play a key role in the potentiation of CCl4 liver injury by chlordecone.	Chlordecone	116-127	C-C motif chemokine ligand 4	Homo sapiens	95-99
2481745-0	1989	Induction of cytochrome P-450 isozymes by mirex and chlordecone.	Chlordecone	52-63	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	13-29
2481745-7	1989	Immunoquantitation with antibodies to purified P-450 IIB1 (Pb-induced P-450) and P-450 IA1 (3-MC-induced P-450) indicated that mirex and chlordecone induced P-450 IIB1 in a dose-dependent manner.	Chlordecone	137-148	insulinoma-associated 1	Mus musculus	87-90
2470164-0	1989	Estradiol and chlordecone interactions with the estradiol receptor.	Chlordecone	14-25	estrogen receptor 1	Rattus norvegicus	48-66
2470164-1	1989	The in vivo and in vitro effects of the chlorinated pesticide, chlordecone, on the estradiol receptor of adult ovariectomized CDF-344 rats were examined.	Chlordecone	63-74	estrogen receptor 1	Rattus norvegicus	83-101
2470164-2	1989	Chlordecone"s competition with [3H]estradiol for binding to the estradiol receptor in vitro was similar whether receptors were derived from neural or uterine tissue.	Chlordecone	0-11	estrogen receptor 1	Rattus norvegicus	64-82
2470164-6	1989	Estradiol receptor replenishment following chlordecone or estradiol was similar in uterine tissue but not in brain.	Chlordecone	43-54	estrogen receptor 1	Rattus norvegicus	0-18
2479360-2	1989	We have recently observed significant protection from CD potentiated CCl4 toxicity in animals which are stimulated for active hepatocellular regeneration.	Chlordecone	54-56	C-C motif chemokine ligand 4	Rattus norvegicus	69-73
2482307-1	1989	Our previous studies indicated the involvement of some unidentified mechanisms, apart from the bioactivation phenomenon, in chlordecone (CD)-potentiated CCl4 hepatotoxicity and lethality.	Chlordecone	124-135	C-C motif chemokine ligand 4	Rattus norvegicus	153-157
2482307-1	1989	Our previous studies indicated the involvement of some unidentified mechanisms, apart from the bioactivation phenomenon, in chlordecone (CD)-potentiated CCl4 hepatotoxicity and lethality.	Chlordecone	137-139	C-C motif chemokine ligand 4	Rattus norvegicus	153-157
2482307-7	1989	CCl4 (100 microliters kg-1)-induced histopathological alterations in CD-pretreated rats were significantly decreased in rats 2 days post-PH (PH2) as compared to SH rats or rats 7 days post-PH (PH7), indicating that amplification of CCl4 toxicity is significantly reduced when there is a greater regenerative activity.	Chlordecone	69-71	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
2482307-7	1989	CCl4 (100 microliters kg-1)-induced histopathological alterations in CD-pretreated rats were significantly decreased in rats 2 days post-PH (PH2) as compared to SH rats or rats 7 days post-PH (PH7), indicating that amplification of CCl4 toxicity is significantly reduced when there is a greater regenerative activity.	Chlordecone	69-71	C-C motif chemokine ligand 4	Rattus norvegicus	232-236
2482307-9	1989	In CD-pretreated PH2 rats where the percentage of mitoses and the percentage of labelled cells were many-fold greater when compared to SH or PH7 rats, a portion of the stimulated hepatocellular division decreased significantly at 2-6 h after CCl4 administration, but remained significantly greater when compared to basal level of regeneration.	Chlordecone	3-5	C-C motif chemokine ligand 4	Rattus norvegicus	242-246
2475629-1	1989	Chlordecone potentiation of the hepatotoxic and lethal effects of CCL4 has been well established.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	66-70
2479360-7	1989	CCl4-induced serum enzyme elevations were significantly lower in 2 days post-PH (PH2) rats when compared to SH rats or 7 days post-PH (PH7) rats maintained on CD diet, indicating that CD potentiated CCl4 hepatotoxicity is significantly reduced in livers stimulated for regenerative activity by PH.	Chlordecone	159-161	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
2479360-7	1989	CCl4-induced serum enzyme elevations were significantly lower in 2 days post-PH (PH2) rats when compared to SH rats or 7 days post-PH (PH7) rats maintained on CD diet, indicating that CD potentiated CCl4 hepatotoxicity is significantly reduced in livers stimulated for regenerative activity by PH.	Chlordecone	184-186	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
2479360-7	1989	CCl4-induced serum enzyme elevations were significantly lower in 2 days post-PH (PH2) rats when compared to SH rats or 7 days post-PH (PH7) rats maintained on CD diet, indicating that CD potentiated CCl4 hepatotoxicity is significantly reduced in livers stimulated for regenerative activity by PH.	Chlordecone	184-186	C-C motif chemokine ligand 4	Rattus norvegicus	199-203
2480256-0	1989	Protection from chlordecone (Kepone)-potentiated CCl4 hepatotoxicity in rats by fructose 1,6-diphosphate.	Chlordecone	29-35	C-C motif chemokine ligand 4	Rattus norvegicus	49-53
2480256-8	1989	These events are consistent with the concept that suppressed hepatocellular regeneration which leads to progression of otherwise limited injury observed in chlordecone potentiation of CCl4 hepatotoxicity is due to lack of cellular energy.	Chlordecone	156-167	C-C motif chemokine ligand 4	Rattus norvegicus	184-188
2451866-0	1988	In vivo metabolism of CCl4 by rats pretreated with chlordecone, mirex, or phenobarbital.	Chlordecone	51-62	C-C motif chemokine ligand 4	Rattus norvegicus	22-26
2483848-1	1989	The potentiation of CCl4 toxicity by pre-exposure to chlordecone (CD) is well established.	Chlordecone	53-64	C-C motif chemokine ligand 4	Rattus norvegicus	20-24
2483848-1	1989	The potentiation of CCl4 toxicity by pre-exposure to chlordecone (CD) is well established.	Chlordecone	66-68	C-C motif chemokine ligand 4	Rattus norvegicus	20-24
2483848-2	1989	Chlordecone-induced metabolism of CCl4 and suppressed hepatocellular repair have been offered as possible mechanisms for this potentiation.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	34-38
2456051-1	1988	Chlordecone (CD) pretreatment is known to markedly potentiate CCl4 hepatotoxicity.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	62-66
2456051-1	1988	Chlordecone (CD) pretreatment is known to markedly potentiate CCl4 hepatotoxicity.	Chlordecone	13-15	C-C motif chemokine ligand 4	Rattus norvegicus	62-66
2456051-2	1988	Previous studies have shown that prior exposure to CD obtunds the increased hepatocellular regeneration and repair observed in non-treated rats challenged with a single, low dose of CCl4.	Chlordecone	51-53	C-C motif chemokine ligand 4	Rattus norvegicus	182-186
2456051-4	1988	To test this hypothesis, CCl4 hepatotoxicity was evaluated in actively regenerating livers using CD-treated (10 ppm in the diet for 15 days), surgically partially hepatectomized (PH) male Sprague-Dawley rats.	Chlordecone	97-99	C-C motif chemokine ligand 4	Rattus norvegicus	25-29
2456051-14	1988	CCl4-induced serum enzyme elevations were significantly less in the CD + PH rats as compared to CD + SH.	Chlordecone	68-72	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
2456051-14	1988	CCl4-induced serum enzyme elevations were significantly less in the CD + PH rats as compared to CD + SH.	Chlordecone	96-100	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
2456051-16	1988	CCl4 lethality, assessed in the 1 day post-surgical manipulation group, was also decreased in the CD + PH rats in comparison to CD + SH rats.	Chlordecone	98-102	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
2456051-16	1988	CCl4 lethality, assessed in the 1 day post-surgical manipulation group, was also decreased in the CD + PH rats in comparison to CD + SH rats.	Chlordecone	98-100	C-C motif chemokine ligand 4	Rattus norvegicus	0-4
2456051-18	1988	These data are consistent with and are supportive of the hypothesis that a suppression of otherwise normally stimulated hepatocellular regeneration following low-dose CCl4 administration is involved in the marked amplification of CCl4 toxicity by CD.	Chlordecone	247-249	C-C motif chemokine ligand 4	Rattus norvegicus	167-171
2456051-18	1988	These data are consistent with and are supportive of the hypothesis that a suppression of otherwise normally stimulated hepatocellular regeneration following low-dose CCl4 administration is involved in the marked amplification of CCl4 toxicity by CD.	Chlordecone	247-249	C-C motif chemokine ligand 4	Rattus norvegicus	230-234
2451866-8	1988	Expiration of 14CO2 measured during the 6 hr after CCl4 administration was increased in animals pretreated with PB or CD.	Chlordecone	118-120	C-C motif chemokine ligand 4	Rattus norvegicus	51-55
2451866-11	1988	These data indicate that a single oral administration of CD (10 mg/kg) 24 hr prior to CCl4 administration (100 microliter/kg) enhances the oxidative metabolism of CCl4 but to a lesser extent than PB (80 mg/kg, ip, twice), which is in inverse relationship to the potentiation of the hepatotoxic and lethal effects of CCl4 associated with these pretreatments.	Chlordecone	57-59	C-C motif chemokine ligand 4	Rattus norvegicus	163-167
2451866-11	1988	These data indicate that a single oral administration of CD (10 mg/kg) 24 hr prior to CCl4 administration (100 microliter/kg) enhances the oxidative metabolism of CCl4 but to a lesser extent than PB (80 mg/kg, ip, twice), which is in inverse relationship to the potentiation of the hepatotoxic and lethal effects of CCl4 associated with these pretreatments.	Chlordecone	57-59	C-C motif chemokine ligand 4	Rattus norvegicus	163-167
2451866-1	1988	The propensity of chlordecone (CD) to potentiate hepatotoxic and lethal effects of CCl4 is well established.	Chlordecone	18-29	C-C motif chemokine ligand 4	Rattus norvegicus	83-87
2451866-1	1988	The propensity of chlordecone (CD) to potentiate hepatotoxic and lethal effects of CCl4 is well established.	Chlordecone	31-33	C-C motif chemokine ligand 4	Rattus norvegicus	83-87
2451866-3	1988	The purpose of this study was to test the possibility that CD potentiates the toxicity of CCl4 by increasing the metabolism of CCl4 to a greater degree than either PB or M. We compared the in vivo metabolism of CCl4 in rats pretreated with CD, M, or PB, by measuring the hepatic content of 14CCl4, the expiration of 14CCl4, expiration of 14CCl4-derived 14CO2, and lipid peroxidation.	Chlordecone	59-61	C-C motif chemokine ligand 4	Rattus norvegicus	90-94
2451866-3	1988	The purpose of this study was to test the possibility that CD potentiates the toxicity of CCl4 by increasing the metabolism of CCl4 to a greater degree than either PB or M. We compared the in vivo metabolism of CCl4 in rats pretreated with CD, M, or PB, by measuring the hepatic content of 14CCl4, the expiration of 14CCl4, expiration of 14CCl4-derived 14CO2, and lipid peroxidation.	Chlordecone	59-61	C-C motif chemokine ligand 4	Rattus norvegicus	127-131
2451866-3	1988	The purpose of this study was to test the possibility that CD potentiates the toxicity of CCl4 by increasing the metabolism of CCl4 to a greater degree than either PB or M. We compared the in vivo metabolism of CCl4 in rats pretreated with CD, M, or PB, by measuring the hepatic content of 14CCl4, the expiration of 14CCl4, expiration of 14CCl4-derived 14CO2, and lipid peroxidation.	Chlordecone	59-61	C-C motif chemokine ligand 4	Rattus norvegicus	127-131
2469047-6	1988	The 5-HT1A agonist, 8-OH-DPAT, was an inefficient competitor for 3H-5-HT binding in frontal cortex of females treated with chlordecone.	Chlordecone	123-134	5-hydroxytryptamine receptor 1A	Rattus norvegicus	4-10
2437290-2	1987	Chlordecone (10-50 microM) increased [Ca++]i from the resting level of 370 nM in a dose- and time-dependent manner to above 1.5 microM.	Chlordecone	0-11	carbonic anhydrase 1	Homo sapiens	38-44
2437290-4	1987	Verapamil, a voltage sensitive Ca++ channel blocker, inhibited the initial increase of [Ca++]i caused by chlordecone, by 40%.	Chlordecone	105-116	carbonic anhydrase 1	Homo sapiens	88-94
2437290-5	1987	Chlordecone also elevated [Ca++]i in synaptosomes in which mitochondrial Ca++ uptake had been abolished by valinomycin.	Chlordecone	0-11	carbonic anhydrase 1	Homo sapiens	27-33
2437290-9	1987	The effect of chlordecone on [Ca++]i decreased when the total amount of tissue in incubations was increased.	Chlordecone	14-25	carbonic anhydrase 1	Homo sapiens	30-36
2436115-0	1987	Modulation of adrenal ornithine decarboxylase by chlordecone, p,p"DDT and permethrin.	Chlordecone	49-60	ornithine decarboxylase 1	Rattus norvegicus	22-45
2469794-1	1987	Chlordecone greatly potentiates carbon tetrachloride (CCl4) hepatotoxicity.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	54-58
2469794-5	1987	Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	75-79
2469794-5	1987	Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls.	Chlordecone	0-11	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	98-140
2469794-5	1987	Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	183-187
2469794-5	1987	Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	183-187
2469794-5	1987	Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls.	Chlordecone	217-228	C-C motif chemokine ligand 4	Rattus norvegicus	75-79
2469794-5	1987	Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls.	Chlordecone	217-228	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	98-140
2469794-5	1987	Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls.	Chlordecone	217-228	C-C motif chemokine ligand 4	Rattus norvegicus	183-187
2469794-5	1987	Chlordecone treatment produced approximately a 17-fold potentiation of the CCl4-dependent loss of cytochrome P-450 and glucose-6-phosphatase activity, so that a dose of 6 microliters CCl4 per 100 g body weight in the chlordecone-treated animals resulted in a similar amount of damage as observed with 100 microliters CCl4 per 100 g body weight in controls.	Chlordecone	217-228	C-C motif chemokine ligand 4	Rattus norvegicus	183-187
2469794-6	1987	A similar potentiation by chlordecone was seen with CCl4 induced increases in serum glutamic-oxaloacetic transaminase (SGOT) levels.	Chlordecone	26-37	C-C motif chemokine ligand 4	Rattus norvegicus	52-56
2469794-7	1987	Chlordecone treatment also increased hepatic cytochrome P-450 levels by 67% and resulted in an increase in the covalent binding of [14-C]-CCl4-derived metabolites to microsomal protein and lipid in vivo.	Chlordecone	0-11	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	45-61
2469794-7	1987	Chlordecone treatment also increased hepatic cytochrome P-450 levels by 67% and resulted in an increase in the covalent binding of [14-C]-CCl4-derived metabolites to microsomal protein and lipid in vivo.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	138-142
2469795-5	1987	Thymidine kinase activity was increased eightfold in CD-treated rats receiving 6 microliters CCl4 per 100 g body weight, whereas in controls a similar induction of TK activity was produced by 100 microliters CCl4 per 100 g body weight.	Chlordecone	53-55	C-C motif chemokine ligand 4	Rattus norvegicus	93-97
2469795-5	1987	Thymidine kinase activity was increased eightfold in CD-treated rats receiving 6 microliters CCl4 per 100 g body weight, whereas in controls a similar induction of TK activity was produced by 100 microliters CCl4 per 100 g body weight.	Chlordecone	53-55	C-C motif chemokine ligand 4	Rattus norvegicus	208-212
2436115-3	1987	The latter dose of chlordecone resulted in a persistent elevation of adrenal ODC for at least 4 days, longer than that caused by the other insecticides examined.	Chlordecone	19-30	ornithine decarboxylase 1	Rattus norvegicus	77-80
2436115-6	1987	Isolated adrenal cortical cells of a mouse tumor line (Y-1), when incubated in media containing 10(-5) M chlordecone, responded with increased ODC activity.	Chlordecone	105-116	ornithine decarboxylase, structural 1	Mus musculus	143-146
3104120-5	1987	At a dose of 500 microliter/kg, cytochrome P-450 and its reductase were decreased by about 25% in the chlordecone-induced gerbil.	Chlordecone	102-113	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	32-48
2439679-3	1987	Technical grade chlordecone produced a dose-dependent inhibition of steroidogenesis in cultured mouse adrenal tumor cells (Y-1 cells) when stimulated with ACTH (IC50 = 4 X 10(-5) M), cAMP (IC50 = 2.3 X 10(-5) M), or pregnenolone (IC50 3.5 X 10(-5) M).	Chlordecone	16-27	pro-opiomelanocortin-alpha	Mus musculus	155-159
2439679-3	1987	Technical grade chlordecone produced a dose-dependent inhibition of steroidogenesis in cultured mouse adrenal tumor cells (Y-1 cells) when stimulated with ACTH (IC50 = 4 X 10(-5) M), cAMP (IC50 = 2.3 X 10(-5) M), or pregnenolone (IC50 3.5 X 10(-5) M).	Chlordecone	16-27	cathelicidin antimicrobial peptide	Mus musculus	183-187
2423933-7	1986	In further studies, chlordecone"s effect on the CNS progesterone receptor was examined.	Chlordecone	20-31	progesterone receptor	Rattus norvegicus	52-73
2482892-1	1986	The effect of carbon tetrachloride (CCl4) on the capacity of hepatic microsomes to sequester calcium was studied following pretreatment of rats with chlordecone.	Chlordecone	149-160	C-C motif chemokine ligand 4	Rattus norvegicus	36-40
2482892-3	1986	It was found, however, that chlordecone pretreatment of rats potentiated by sixfold the potency of CCl4 to suppress microsomal calcium sequestration capacity when measured one hour after CCl4 administration.	Chlordecone	28-39	C-C motif chemokine ligand 4	Rattus norvegicus	99-103
2482892-3	1986	It was found, however, that chlordecone pretreatment of rats potentiated by sixfold the potency of CCl4 to suppress microsomal calcium sequestration capacity when measured one hour after CCl4 administration.	Chlordecone	28-39	C-C motif chemokine ligand 4	Rattus norvegicus	187-191
2435023-0	1987	Comparative changes in hepatic DNA, RNA, protein, lipid, and glycogen induced by a subtoxic dose of CCl4 in chlordecone, mirex, and phenobarbital pretreated rats.	Chlordecone	108-119	C-C motif chemokine ligand 4	Rattus norvegicus	100-104
2435023-5	1987	A significant decrease (18%) in hepatic protein was observed 24 h after CCl4 challenge in the CD-pretreated rats; significant changes were not observed in the other treatment groups.	Chlordecone	94-96	C-C motif chemokine ligand 4	Rattus norvegicus	72-76
2435023-8	1987	Lipid content was increased at all time points starting at 4 h in response to CCl4 challenge in the CD-pretreated rats.	Chlordecone	100-102	C-C motif chemokine ligand 4	Rattus norvegicus	78-82
2435023-13	1987	These studies indicate that biochemical changes compatible with cellular death are more pronounced in the CD-pretreated rats than in those receiving CCl4 alone, suggesting that the metabolic and supportive biochemical mechanisms for hepatocellular repair are suppressed in rats receiving CD + CCl4.	Chlordecone	106-108	C-C motif chemokine ligand 4	Rattus norvegicus	293-297
2435023-13	1987	These studies indicate that biochemical changes compatible with cellular death are more pronounced in the CD-pretreated rats than in those receiving CCl4 alone, suggesting that the metabolic and supportive biochemical mechanisms for hepatocellular repair are suppressed in rats receiving CD + CCl4.	Chlordecone	288-290	C-C motif chemokine ligand 4	Rattus norvegicus	149-153
2435068-2	1987	Treatment with chlordecone resulted in a two- to three-fold increase in cytochrome P-450 content but the BP-hydroxylase activity per mg microsomal protein was unaffected.	Chlordecone	15-26	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	72-88
2421457-2	1986	We have reported even greater accumulation of cytosolic Ca2+ in animals treated with an ordinarily nontoxic dose of CCl4 in combination with prior exposure to chlordecone (CD).	Chlordecone	172-174	C-C motif chemokine ligand 4	Rattus norvegicus	116-120
2412926-0	1985	The effect of dietary exposure to a mirex plus chlordecone combination on CCl4 hepatotoxicity.	Chlordecone	47-58	C-C motif chemokine ligand 4	Rattus norvegicus	74-78
2412926-1	1985	The purpose of these studies was to investigate the effect of a mirex plus chlordecone combination on CCl4-induced hepatotoxicity.	Chlordecone	75-86	C-C motif chemokine ligand 4	Rattus norvegicus	102-106
2412926-10	1985	These results provide additional evidence that CD pretreatment results in a rather specific sensitization of animals to CCl4 toxicity in ways independent of the actions of M.	Chlordecone	47-49	C-C motif chemokine ligand 4	Rattus norvegicus	120-124
2416942-0	1985	Chlordecone inhibition of calmodulin activated calcium ATPase in rat brain synaptosomes.	Chlordecone	0-11	calmodulin 1	Rattus norvegicus	26-36
2579844-1	1985	Administration of isopropanol (2.5 ml/kg, po) or chlordecone (15.2 mg/kg, po) potentiated the release of glutamic oxaloacetic transaminase (GOT) into serum 17- or 7-fold, respectively, in rats exposed subsequently to 30 microliter CCl4/kg, po.	Chlordecone	49-60	C-C motif chemokine ligand 4	Rattus norvegicus	231-235
2579844-5	1985	The same dose and time-dependent pattern of potentiated GOT release upon exposure of CCl4 was seen in hepatocytes obtained from chlordecone-treated rats.	Chlordecone	128-139	C-C motif chemokine ligand 4	Rattus norvegicus	85-89
2579844-6	1985	These results indicate that the potentiation by isopropanol or chlordecone of CCl4-induced release of GOT from liver is retained through the procedures of cell isolation.	Chlordecone	63-74	C-C motif chemokine ligand 4	Rattus norvegicus	78-82
2581193-7	1985	Similarly, chlordecone treatment reduced the pituitary content of enkephalin in a manner identical to that of estrogen.	Chlordecone	11-22	proenkephalin	Rattus norvegicus	66-76
2581193-15	1985	Moreover, due to the similarity of both estrogen and chlordecone to anti-dopaminergic agents in altering [Met5]-enkephalin levels in both the pituitary and caudate nucleus it is speculated that a dopaminergic mechanism is responsible for their actions on the enkephalin system.	Chlordecone	53-64	proenkephalin	Rattus norvegicus	112-122
2581193-15	1985	Moreover, due to the similarity of both estrogen and chlordecone to anti-dopaminergic agents in altering [Met5]-enkephalin levels in both the pituitary and caudate nucleus it is speculated that a dopaminergic mechanism is responsible for their actions on the enkephalin system.	Chlordecone	53-64	proenkephalin	Rattus norvegicus	259-269
2581195-3	1985	In ovariectomized females, chlordecone reduced serum levels of luteinizing hormone (LH) and increased prolactin (PRL).	Chlordecone	27-38	prolactin	Rattus norvegicus	102-111
2581195-9	1985	We have proposed that chlordecone mimics many of the estrogen-receptor mediated neural events.	Chlordecone	22-33	estrogen receptor 1	Rattus norvegicus	53-70
2416942-3	1985	Chlordecone inhibited Ca2+-ATPase in the absence of calmodulin with an IC50 of 10 microM, whereas chlordecone at 1.0 microM, which had no effect on the basal enzyme activity, completely inhibited the calmodulin activated Ca2+-ATPase.	Chlordecone	0-11	calmodulin 1	Rattus norvegicus	200-210
2416942-3	1985	Chlordecone inhibited Ca2+-ATPase in the absence of calmodulin with an IC50 of 10 microM, whereas chlordecone at 1.0 microM, which had no effect on the basal enzyme activity, completely inhibited the calmodulin activated Ca2+-ATPase.	Chlordecone	98-109	calmodulin 1	Rattus norvegicus	200-210
2416942-4	1985	Chlordecone-treated rats showed a significant reduction in calmodulin levels in brain P2 fraction.	Chlordecone	0-11	calmodulin 1	Rattus norvegicus	59-69
2416942-5	1985	Brain synaptosomal Ca2+-ATPase in chlordecone-treated rats showed a 50% reduction, which was restored by exogenously added calmodulin.	Chlordecone	34-45	calmodulin 1	Rattus norvegicus	123-133
2416942-6	1985	These results suggest that chlordecone may be altering calmodulin-regulated synaptic processes in the brain.	Chlordecone	27-38	calmodulin 1	Rattus norvegicus	55-65
6209127-0	1984	Perturbation of calcium homeostasis by CCl4 in rats pretreated with chlordecone and phenobarbital.	Chlordecone	68-79	C-C motif chemokine ligand 4	Rattus norvegicus	39-43
6209127-3	1984	Induction of cytochrome P-450 was greater with phenobarbital treatment than with chlordecone, but the CCl4-induced destruction of P-450 was similar in both groups and was progressive with the dose of CCl4 and with time after CCl4 administration.	Chlordecone	81-92	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	13-29
6209127-9	1984	These findings suggest that excessive Ca2+ accumulation may be related to the progression of hepatotoxic response to CCl4 in CD-treated animals.	Chlordecone	125-127	C-C motif chemokine ligand 4	Rattus norvegicus	117-121
6209127-5	1984	These findings are consistent with greater bioactivation of CCl4 after the above two pretreatments There was a massive accumulation of Ca2+ in CD- and PB-pretreated animals after CCl4 administration, CD being more effective in this regard.	Chlordecone	143-145	C-C motif chemokine ligand 4	Rattus norvegicus	60-64
6209127-5	1984	These findings are consistent with greater bioactivation of CCl4 after the above two pretreatments There was a massive accumulation of Ca2+ in CD- and PB-pretreated animals after CCl4 administration, CD being more effective in this regard.	Chlordecone	143-145	C-C motif chemokine ligand 4	Rattus norvegicus	179-183
6209127-5	1984	These findings are consistent with greater bioactivation of CCl4 after the above two pretreatments There was a massive accumulation of Ca2+ in CD- and PB-pretreated animals after CCl4 administration, CD being more effective in this regard.	Chlordecone	200-202	C-C motif chemokine ligand 4	Rattus norvegicus	60-64
6209127-7	1984	This perturbation of hepatocellular Ca2+ homeostasis which occurs 3 to 6 hr after CCl4 may prevent hepatocellular repair and renovation in CD-treated animals, leading to progressive hepatic lesion, hepatic failure and animal death by 36 to 48 hr at nontoxic doses of CCl4.	Chlordecone	139-141	C-C motif chemokine ligand 4	Rattus norvegicus	82-86
6209127-7	1984	This perturbation of hepatocellular Ca2+ homeostasis which occurs 3 to 6 hr after CCl4 may prevent hepatocellular repair and renovation in CD-treated animals, leading to progressive hepatic lesion, hepatic failure and animal death by 36 to 48 hr at nontoxic doses of CCl4.	Chlordecone	139-141	C-C motif chemokine ligand 4	Rattus norvegicus	267-271
6199870-0	1984	Chlordecone potentiation of CCl4 hepatotoxicity in ovariectomized rats.	Chlordecone	0-11	C-C motif chemokine ligand 4	Rattus norvegicus	28-32
6204421-2	1984	A single injection (25 to 75 mg/kg, ip) or repeated injections (2.5 to 10 mg/kg/day for 10 days, ip) of chlordecone caused a time- and dose-related decrease in pituitary [Met5]-enkephalin-like immunoreactivity (ME-LI) in adult rats.	Chlordecone	104-115	proenkephalin	Rattus norvegicus	177-187
6204898-1	1984	The propensity for chlordecone to potentiate hepatotoxicity of CCl4 and some related analogs (CHCl3 and CBrCl3) has been well established.	Chlordecone	19-30	C-C motif chemokine ligand 4	Homo sapiens	63-67
6204898-4	1984	The chlordecone + CCl4 interaction occurs in animals of both sexes and is characterized by profoundly potentiated lethality.	Chlordecone	4-15	C-C motif chemokine ligand 4	Homo sapiens	18-22
6204898-8	1984	Time-course studies in which liver tissue was examined 1 to 36 hr after CCl4 administration to chlordecone treated animals revealed possible mechanisms.	Chlordecone	95-106	C-C motif chemokine ligand 4	Homo sapiens	72-76
6204898-9	1984	It appears that a greater bioactivation of CCl4 in chlordecone treated animals resulted in an initial potentiation of toxic events in the liver cells.	Chlordecone	51-62	C-C motif chemokine ligand 4	Homo sapiens	43-47
6204898-10	1984	While animals receiving a normally nontoxic dose of CCl4 alone demonstrate repair and renovation of liver tissue as revealed by greatly increased mitotic index after 12 hours, such a renovation process is totally suppressed in animals exposed to chlordecone.	Chlordecone	246-257	C-C motif chemokine ligand 4	Homo sapiens	52-56
6204898-12	1984	The greater initial liver injury is consistent with enhanced metabolism and bioactivation of CCl4 in chlordecone exposed animals.	Chlordecone	101-112	C-C motif chemokine ligand 4	Homo sapiens	93-97
6204898-16	1984	First, chlordecone induction of a specific form of P-450 capable of greater bioactivation of CCl4.	Chlordecone	7-18	C-C motif chemokine ligand 4	Homo sapiens	93-97
6199871-0	1984	Excessive hepatic accumulation of intracellular Ca2+ in chlordecone potentiated CCl4 toxicity.	Chlordecone	56-67	C-C motif chemokine ligand 4	Rattus norvegicus	80-84
6199871-1	1984	The possible role of Ca2+ in chlordecone potentiation of CCl4 hepatotoxicity was examined in male Sprague-Dawley rats.	Chlordecone	29-40	C-C motif chemokine ligand 4	Rattus norvegicus	57-61
6199871-7	1984	Administration of CCl4 at an otherwise non-toxic dose to chlordecone treated animals resulted in significant increases of whole liver and subcellular Ca2+ as compared to chlordecone alone and CCl4 alone with a characteristic biphasic response.	Chlordecone	57-68	C-C motif chemokine ligand 4	Rattus norvegicus	18-22
6199871-7	1984	Administration of CCl4 at an otherwise non-toxic dose to chlordecone treated animals resulted in significant increases of whole liver and subcellular Ca2+ as compared to chlordecone alone and CCl4 alone with a characteristic biphasic response.	Chlordecone	57-68	C-C motif chemokine ligand 4	Rattus norvegicus	192-196
6199871-7	1984	Administration of CCl4 at an otherwise non-toxic dose to chlordecone treated animals resulted in significant increases of whole liver and subcellular Ca2+ as compared to chlordecone alone and CCl4 alone with a characteristic biphasic response.	Chlordecone	170-181	C-C motif chemokine ligand 4	Rattus norvegicus	18-22
6199871-10	1984	The increases were all progressive with increases in dietary levels of chlordecone, indicating that chlordecone-induced sensitivity is responsible for CCl4 elicited perturbations in whole liver and intracellular Ca2+ levels.	Chlordecone	71-82	C-C motif chemokine ligand 4	Rattus norvegicus	151-155
6199871-10	1984	The increases were all progressive with increases in dietary levels of chlordecone, indicating that chlordecone-induced sensitivity is responsible for CCl4 elicited perturbations in whole liver and intracellular Ca2+ levels.	Chlordecone	100-111	C-C motif chemokine ligand 4	Rattus norvegicus	151-155
6199871-11	1984	This study suggests that chlordecone modifies the liver plasma membrane to amplify the CCl4 elicited perturbations in hepatocellular Ca2+ homeostasis especially during 6-12 h after CCl4 administration.	Chlordecone	25-36	C-C motif chemokine ligand 4	Rattus norvegicus	87-91
6199871-11	1984	This study suggests that chlordecone modifies the liver plasma membrane to amplify the CCl4 elicited perturbations in hepatocellular Ca2+ homeostasis especially during 6-12 h after CCl4 administration.	Chlordecone	25-36	C-C motif chemokine ligand 4	Rattus norvegicus	181-185
6199870-2	1984	The present study was designed to investigate the hepatotoxicity of CCl4 in chlordecone (CD) pretreated, ovariectomized rats.	Chlordecone	76-87	C-C motif chemokine ligand 4	Rattus norvegicus	68-72
6199870-8	1984	This study suggests that chlordecone sensitizes the liver in ovariectomized rats as well to amplify the toxic effects of CCl4.	Chlordecone	25-36	C-C motif chemokine ligand 4	Rattus norvegicus	121-125
6194013-1	1983	The present study, conducted over a time course of 36 hr after CCl4 administration, describes sequential morphometric and biochemical changes which occur in livers of rats exposed to a combination of low levels of chlordecone (10 ppm for 15 days) and a single ip injection of CCl4 (0.1 ml/kg).	Chlordecone	214-225	C-C motif chemokine ligand 4	Rattus norvegicus	63-67
6196592-0	1983	Destruction of hepatic mixed-function oxygenase parameters by CCl4 in rats following acute treatment with chlordecone, Mirex, and phenobarbital.	Chlordecone	106-117	C-C motif chemokine ligand 4	Rattus norvegicus	62-66
6196592-1	1983	Previous work has established the marked potentiation of CCl4 hepatoxicity by prior exposure to chlordecone (CD).	Chlordecone	96-107	C-C motif chemokine ligand 4	Rattus norvegicus	57-61
6196592-1	1983	Previous work has established the marked potentiation of CCl4 hepatoxicity by prior exposure to chlordecone (CD).	Chlordecone	109-111	C-C motif chemokine ligand 4	Rattus norvegicus	57-61
6196592-2	1983	This study was conducted to determine if prior exposure to CD results in enhancement of CCl4-induced destruction of the hepatic microsomal mixed-function oxygenase (MFO) system.	Chlordecone	59-61	C-C motif chemokine ligand 4	Rattus norvegicus	88-92
6196592-7	1983	As previously demonstrated using a subchronic dietary pretreatment protocol, CD potentiated CCl4 hepatotoxicity over a range of CCl4 doses to a greater extent than PB or M, as judged by elevations in serum enzymes.	Chlordecone	77-79	C-C motif chemokine ligand 4	Rattus norvegicus	92-96
6196592-7	1983	As previously demonstrated using a subchronic dietary pretreatment protocol, CD potentiated CCl4 hepatotoxicity over a range of CCl4 doses to a greater extent than PB or M, as judged by elevations in serum enzymes.	Chlordecone	77-79	C-C motif chemokine ligand 4	Rattus norvegicus	128-132
6196592-10	1983	CD treatment caused the greatest decrease in G-6-Pase activity in comparison to PB or M pretreatments and a similar degree of P-450 destruction as observed with the PB group.	Chlordecone	0-2	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	45-53
6196592-11	1983	These findings suggest that in general, CCl4-induced destruction of hepatic MFO parameters measured in this study is disproportional to the known degree of potentiated hepatotoxicity by the pretreatments and does not accurately reflect the potentiation of CCl4 hepatotoxicity by CD.	Chlordecone	279-281	C-C motif chemokine ligand 4	Rattus norvegicus	40-44
6194012-1	1983	Previous studies have shown that a chlorinated pesticide, chlordecone (Kepone), greatly potentiates carbon tetrachloride (CCl4) hepatotoxicity and lethality (Curtis, L.R., Williams, W.L., and Mehendale, H.M. (1979).	Chlordecone	58-69	C-C motif chemokine ligand 4	Rattus norvegicus	122-126
6194012-1	1983	Previous studies have shown that a chlorinated pesticide, chlordecone (Kepone), greatly potentiates carbon tetrachloride (CCl4) hepatotoxicity and lethality (Curtis, L.R., Williams, W.L., and Mehendale, H.M. (1979).	Chlordecone	71-77	C-C motif chemokine ligand 4	Rattus norvegicus	122-126
6194012-17	1983	Prior administration of chlordecone greatly potentiated pathologic changes in livers of animals that received CCl4.	Chlordecone	24-35	C-C motif chemokine ligand 4	Rattus norvegicus	110-114
6194012-25	1983	This study indicates that although the combination of chlordecone and CCl4 produces much greater hepatic injury resembling damage due to a massive dose of CCl4, histologically, some differences in the progression and distribution of hepatocellular damage within the lobular architecture of the liver are evident.	Chlordecone	54-65	C-C motif chemokine ligand 4	Rattus norvegicus	155-159
6192011-0	1983	Acute hepatotoxicity and lethality of CCl4 in chlordecone-pretreated rats.	Chlordecone	46-57	C-C motif chemokine ligand 4	Rattus norvegicus	38-42
6198234-1	1983	The propensity of chlordecone (CD) to potentiate CCl4 hepatotoxicity in rats of either sex has been well documented.	Chlordecone	18-29	C-C motif chemokine ligand 4	Rattus norvegicus	49-53
6198234-1	1983	The propensity of chlordecone (CD) to potentiate CCl4 hepatotoxicity in rats of either sex has been well documented.	Chlordecone	31-33	C-C motif chemokine ligand 4	Rattus norvegicus	49-53
6198234-8	1983	These data indicate that the capacity of CD to potentiate CCl4 hepatotoxicity is unaffected in adrenalectomized rats.	Chlordecone	41-43	C-C motif chemokine ligand 4	Rattus norvegicus	58-62
6192011-1	1983	In a subchronic dietary pretreatment protocol chlordecone (CD) is a powerful potentiator of CCl4 hepatotoxicity, as indicated by biochemical, hepatofunctional, histopathological, and lethality parameters.	Chlordecone	46-57	C-C motif chemokine ligand 4	Rattus norvegicus	92-96
6192011-9	1983	These findings indicate that the acute pretreatment with CD enhances hepatotoxicity and the lethality of CCl4 in a fashion qualitatively similar to the subchronic pretreatment protocol.	Chlordecone	57-59	C-C motif chemokine ligand 4	Rattus norvegicus	105-109
6192011-1	1983	In a subchronic dietary pretreatment protocol chlordecone (CD) is a powerful potentiator of CCl4 hepatotoxicity, as indicated by biochemical, hepatofunctional, histopathological, and lethality parameters.	Chlordecone	59-61	C-C motif chemokine ligand 4	Rattus norvegicus	92-96
6192011-2	1983	The purpose of this investigation is to further explore the CD + CCl4 interaction in an acute CD pretreatment protocol and to compare the two pretreatment protocols in terms of their effect upon quantitative histopathology, serum enzymes, and lethality.	Chlordecone	94-96	C-C motif chemokine ligand 4	Rattus norvegicus	65-69
6193935-0	1983	Hepatic microsomal metabolism of CCL4 after pretreatment with chlordecone, mirex, or phenobarbital in male rats.	Chlordecone	62-73	C-C motif chemokine ligand 4	Rattus norvegicus	33-37
6194576-4	1983	CBr4 caused renal dysfunction characterized by oliguria, aciduria and hypo-osmolality, and these effects were abolished by dietary CD pretreatment.	Chlordecone	131-133	carbonyl reductase 4	Rattus norvegicus	0-4
6154986-0	1980	Functional and biochemical correlates of chlordecone exposure and its enhancement of CCl4 hepatotoxicity.	Chlordecone	41-52	C-C motif chemokine ligand 4	Homo sapiens	85-89
6190268-0	1983	Potentiation of CCl4 hepatotoxicity and lethality by chlordecone in female rats.	Chlordecone	53-64	C-C motif chemokine ligand 4	Rattus norvegicus	16-20
6186955-3	1982	A single injection of chlordecone (1 mg/pup on day 4 of age) reduced the level of [Met5]-enkephalin at 70 and 120 days of age in male rats but not in females.	Chlordecone	22-33	proenkephalin	Rattus norvegicus	89-99
6186955-6	1982	These results suggest that hypothalamo-pituitary axis may be the primary neural target affected by chlordecone and estrogen-like activity may be related to the chlordecone-elicited decrease in pituitary [Met5]-enkephalin level.	Chlordecone	160-171	proenkephalin	Rattus norvegicus	210-220
6178186-0	1982	Potentiation of CCl4 lethality by chlordecone.	Chlordecone	34-45	C-C motif chemokine ligand 4	Rattus norvegicus	16-20
6178186-1	1982	Previous studies have dealt with the propensity of chlordecone (CD) to potentiate the hepatotoxicity of CCl4.	Chlordecone	51-62	C-C motif chemokine ligand 4	Rattus norvegicus	104-108
6178186-1	1982	Previous studies have dealt with the propensity of chlordecone (CD) to potentiate the hepatotoxicity of CCl4.	Chlordecone	64-66	C-C motif chemokine ligand 4	Rattus norvegicus	104-108
6178186-3	1982	The objective of the present study was to evaluate the effect of CD on CCl4 lethality and several parameters associated with cytochrome P-450 activity.	Chlordecone	65-67	C-C motif chemokine ligand 4	Rattus norvegicus	71-75
6178186-8	1982	CD decrease the LD50 of CCl4 from 2.8 ml/kg to 0.042 ml/kg, representing a 67-fold increase in toxicity, as assessed by lethality.	Chlordecone	0-2	C-C motif chemokine ligand 4	Rattus norvegicus	24-28
6178186-14	1982	These results remain consistent with the proposal that bioactivation is the mechanisms underlying enhanced CCl4 toxicity, but suggest that specific effects of CD upon CCl4 metabolism may be the pivotal mechanism underlying potentiation.	Chlordecone	159-161	C-C motif chemokine ligand 4	Rattus norvegicus	167-171
6158768-1	1980	The effect of chlordecone on the mouse brain synaptosomal Na+-K+ ATPase, Mg2+ ATPase and p-nitrophenyl phosphatase (PNPPase) activities was determined.	Chlordecone	14-25	dynein, axonemal, heavy chain 8	Mus musculus	65-71
6158768-3	1980	The in vitro data show that chlordecone inhibits PNPPase, Na+-K+ ATPase, and Mg2+ ATPase activities with ID50 values of 4, 5 and 7 micrograms respectively.	Chlordecone	28-39	dynein, axonemal, heavy chain 8	Mus musculus	65-71
6158768-3	1980	The in vitro data show that chlordecone inhibits PNPPase, Na+-K+ ATPase, and Mg2+ ATPase activities with ID50 values of 4, 5 and 7 micrograms respectively.	Chlordecone	28-39	dynein, axonemal, heavy chain 8	Mus musculus	82-88
6154986-11	1980	Thus, while the mechanism for the enhanced toxicity remains to be elucidated, these results suggest that the interaction between chlordecone and CCl4 is a subtle one, not causally involving increased covalent binding of the toxin, increased susceptibility of tissue lipids to peroxidative damage or decreased hepatic GSH.	Chlordecone	129-140	C-C motif chemokine ligand 4	Homo sapiens	145-149
6154986-1	1980	Animals pretreated with chlordecone exhibit a greatly increased hepatotoxic response to CCl4 challenge.	Chlordecone	24-35	C-C motif chemokine ligand 4	Homo sapiens	88-92
93289-1	1979	The chlorinated insecticide chlordecone (Kepone) interacts with the estrogen receptor system in the rat uterus in vitro and in vivo.	Chlordecone	28-39	estrogen receptor 1	Rattus norvegicus	68-85
93289-1	1979	The chlorinated insecticide chlordecone (Kepone) interacts with the estrogen receptor system in the rat uterus in vitro and in vivo.	Chlordecone	41-47	estrogen receptor 1	Rattus norvegicus	68-85
93289-3	1979	When injected into immature rats, chlordecone translocates estrogen receptor sites to the uterine nucleus, increases uterine weight, and stimulates the synthesis of the progesterone receptor, an estrogen receptor-mediated process.	Chlordecone	34-45	estrogen receptor 1	Rattus norvegicus	59-76
93289-3	1979	When injected into immature rats, chlordecone translocates estrogen receptor sites to the uterine nucleus, increases uterine weight, and stimulates the synthesis of the progesterone receptor, an estrogen receptor-mediated process.	Chlordecone	34-45	progesterone receptor	Rattus norvegicus	169-190
93289-3	1979	When injected into immature rats, chlordecone translocates estrogen receptor sites to the uterine nucleus, increases uterine weight, and stimulates the synthesis of the progesterone receptor, an estrogen receptor-mediated process.	Chlordecone	34-45	estrogen receptor 1	Rattus norvegicus	195-212
78523-1	1978	Kepone induces ovalbumin and conalbumin synthesis in explants of chick oviduct in vitro by acting as a weak estrogen.	Chlordecone	0-6	ovalbumin (SERPINB14)	Gallus gallus	15-24
78523-1	1978	Kepone induces ovalbumin and conalbumin synthesis in explants of chick oviduct in vitro by acting as a weak estrogen.	Chlordecone	0-6	transferrin (ovotransferrin)	Gallus gallus	29-39
25302347-0	1976	Report on Carcinogenesis Bioassay of Technical Grade Chlordecone (Kepone) (CAS No.	Chlordecone	53-64	breast cancer anti-estrogen resistance 1	Mus musculus	75-78
25302347-0	1976	Report on Carcinogenesis Bioassay of Technical Grade Chlordecone (Kepone) (CAS No.	Chlordecone	66-72	breast cancer anti-estrogen resistance 1	Mus musculus	75-78
29452237-1	2018	AIM: Chlordecone is able to induce pro-angiogenic effect through an estrogen receptor (ERalpha) pathway involving NO release and VEGF.	Chlordecone	5-16	estrogen receptor 1	Homo sapiens	87-94
33711761-18	2021	ChIP-seq analysis showed that 129 regions in F1 and 240 in F3 acquired altered H3K4me3 occupancy in CD-derived prostate, including highest increase at several promoters of Hoxa family genes in both datasets.	Chlordecone	100-102	homeobox A cluster	Mus musculus	172-176
32044482-4	2020	In the in vitro assays, single chlordecone treatments promoted growth hormone (GH) and prolactin (PRL) secretion in GH3 cells.	Chlordecone	31-42	gonadotropin releasing hormone receptor	Rattus norvegicus	63-77
32044482-4	2020	In the in vitro assays, single chlordecone treatments promoted growth hormone (GH) and prolactin (PRL) secretion in GH3 cells.	Chlordecone	31-42	gonadotropin releasing hormone receptor	Rattus norvegicus	79-81
32044482-4	2020	In the in vitro assays, single chlordecone treatments promoted growth hormone (GH) and prolactin (PRL) secretion in GH3 cells.	Chlordecone	31-42	prolactin	Rattus norvegicus	87-96
32044482-4	2020	In the in vitro assays, single chlordecone treatments promoted growth hormone (GH) and prolactin (PRL) secretion in GH3 cells.	Chlordecone	31-42	prolactin	Rattus norvegicus	98-101
32044482-6	2020	When co-treated with T3, chlordecone acted independently of the effect of T3 on GH secretion; chlordecone-induced GH/PRL secretion and mRNA expression were further promoted when co-treated with E2, but inhibited when co-treated with ICI, indicating an important role for estrogen receptors (ERs) in chlordecone-induced changes in GH3 cells.	Chlordecone	94-105	prolactin	Rattus norvegicus	117-120
32044482-6	2020	When co-treated with T3, chlordecone acted independently of the effect of T3 on GH secretion; chlordecone-induced GH/PRL secretion and mRNA expression were further promoted when co-treated with E2, but inhibited when co-treated with ICI, indicating an important role for estrogen receptors (ERs) in chlordecone-induced changes in GH3 cells.	Chlordecone	94-105	prolactin	Rattus norvegicus	117-120
29452237-1	2018	AIM: Chlordecone is able to induce pro-angiogenic effect through an estrogen receptor (ERalpha) pathway involving NO release and VEGF.	Chlordecone	5-16	vascular endothelial growth factor A	Homo sapiens	129-133
29452237-4	2018	The ROS scavenger MnTMPyP was able to prevent the increase of both VEGF expression and capillary length induced by chlordecone.	Chlordecone	115-126	vascular endothelial growth factor A	Homo sapiens	67-71
29452237-5	2018	A significant increase of cytoplasmic O2- production was observed after 1 and 4 h incubation of chlordecone, but not after 2 h. The NADPH oxidase inhibitor apocynin or silencing p47phox prevented angiogenesis and tube formation but also the increase in production of O2- at 1 h. In addition, apocynin as well silencing p47phox prevented eNOS activation and the NO synthase inhibitor L-NAME inhibited mitochondrial O2-production.	Chlordecone	96-107	neutrophil cytosolic factor 1	Homo sapiens	178-185
29452237-5	2018	A significant increase of cytoplasmic O2- production was observed after 1 and 4 h incubation of chlordecone, but not after 2 h. The NADPH oxidase inhibitor apocynin or silencing p47phox prevented angiogenesis and tube formation but also the increase in production of O2- at 1 h. In addition, apocynin as well silencing p47phox prevented eNOS activation and the NO synthase inhibitor L-NAME inhibited mitochondrial O2-production.	Chlordecone	96-107	neutrophil cytosolic factor 1	Homo sapiens	319-326
29452237-8	2018	Finally, we showed that chlordecone induces endothelial cells angiogenesis by a cross-talk involving NADPH oxidase and mitochondrial O2-via a NO sensitive pathways through activation of ERalpha.	Chlordecone	24-35	estrogen receptor 1	Homo sapiens	186-193
26853152-8	2016	The co-exposure of mice to CCl4 and chlordecone resulted in significant increases in ALT and AST levels.	Chlordecone	36-47	glutamic pyruvic transaminase, soluble	Mus musculus	85-88
26853152-8	2016	The co-exposure of mice to CCl4 and chlordecone resulted in significant increases in ALT and AST levels.	Chlordecone	36-47	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	93-96
26853152-9	2016	Chlordecone also increased expression of the Col1A2, MMP-2, TIMP-1 and PAI-1 genes in CCl4-treated mice.	Chlordecone	0-11	matrix metallopeptidase 2	Mus musculus	53-58
26853152-9	2016	Chlordecone also increased expression of the Col1A2, MMP-2, TIMP-1 and PAI-1 genes in CCl4-treated mice.	Chlordecone	0-11	tissue inhibitor of metalloproteinase 1	Mus musculus	60-66
26853152-9	2016	Chlordecone also increased expression of the Col1A2, MMP-2, TIMP-1 and PAI-1 genes in CCl4-treated mice.	Chlordecone	0-11	collagen, type I, alpha 2	Mus musculus	45-51
26853152-9	2016	Chlordecone also increased expression of the Col1A2, MMP-2, TIMP-1 and PAI-1 genes in CCl4-treated mice.	Chlordecone	0-11	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	71-76
26853152-9	2016	Chlordecone also increased expression of the Col1A2, MMP-2, TIMP-1 and PAI-1 genes in CCl4-treated mice.	Chlordecone	0-11	chemokine (C-C motif) ligand 4	Mus musculus	86-90
18951962-8	2008	On the other hand, both chlordecone and E2 increased Bcl-2 expression in CD4 T-cells and reduced CD4 T-cell apoptosis without affecting their proliferation.	Chlordecone	24-35	B cell leukemia/lymphoma 2	Mus musculus	53-58
26853152-10	2016	Finally, we demonstrated, by quantifying areas of collagen deposition and alpha-SMA gene expression, that chlordecone potentiated the hepatic fibrosis induced by CCl4.	Chlordecone	106-117	actin alpha 2, smooth muscle, aorta	Mus musculus	74-83
26853152-10	2016	Finally, we demonstrated, by quantifying areas of collagen deposition and alpha-SMA gene expression, that chlordecone potentiated the hepatic fibrosis induced by CCl4.	Chlordecone	106-117	chemokine (C-C motif) ligand 4	Mus musculus	162-166
26853152-11	2016	In conclusion, our data suggest that chlordecone potentiates hepatic fibrosis in mice with CCl4-induced chronic liver injury.	Chlordecone	37-48	chemokine (C-C motif) ligand 4	Mus musculus	91-95
26184709-3	2015	The aim of our work was to include chlordecone in a multi organochlorine residue method preventing any degradation during the analytical process and thus allowing quantification at ppt (ngkg(-1) or ngL(-1)) levels for a wide range of OCPs in breast milk, human serum and adipose tissue.	Chlordecone	35-46	leucine rich repeat containing 4C	Homo sapiens	198-204
22829064-4	2012	The present study aimed at investigating the effects of lindane and chlordecone on cellular processes leading to angiogenesis through an involvement of ERalpha.	Chlordecone	68-79	estrogen receptor 1	Homo sapiens	152-159
18951962-9	2008	Although both treatments increased TNF-alpha and IL-2 secretion by CD4 T-cells, only chlordecone increased secretion of IFN-gamma and GM-CSF.	Chlordecone	85-96	interferon gamma	Mus musculus	120-129
18951962-9	2008	Although both treatments increased TNF-alpha and IL-2 secretion by CD4 T-cells, only chlordecone increased secretion of IFN-gamma and GM-CSF.	Chlordecone	85-96	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	134-140
23384675-11	2013	Endosulfan and kepone (group 3) weakly activated ERalpha.	Chlordecone	15-21	estrogen receptor 1	Homo sapiens	49-56
19666090-5	2009	Western blotting demonstrated that a single dose of CD promoted subcellular distribution of SR-BII to murine hepatic microsomes about 2.2-fold when compared to controls without effect on liver crude membrane SR-BII content.	Chlordecone	52-54	scavenger receptor class B member 2	Homo sapiens	92-98
18789348-0	2008	Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice.	Chlordecone	0-11	nuclear receptor subfamily 1, group I, member 2	Mus musculus	21-40
18789348-0	2008	Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice.	Chlordecone	0-11	nuclear receptor subfamily 1, group I, member 2	Mus musculus	42-45
18789348-10	2008	At 14 days after 15 mg CD/kg apoA-I and apoB-100 proteins but not CYP3A11 protein in hepatic microsomes are similar to controls.	Chlordecone	23-25	apolipoprotein A-I	Mus musculus	29-35
18789348-0	2008	Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice.	Chlordecone	0-11	estrogen receptor 1 (alpha)	Mus musculus	51-74
18789348-0	2008	Chlordecone, a mixed pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) agonist, alters cholesterol homeostasis and lipoprotein metabolism in C57BL/6 mice.	Chlordecone	0-11	estrogen receptor 1 (alpha)	Mus musculus	76-83
18789348-5	2008	In this study, we report that CD suppresses in vitro reporter systems for human liver X receptors (LXRs) and activates those for human farnesoid X receptor (FXR), pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) in a concentration-dependent manner (0-50 muM).	Chlordecone	30-32	nuclear receptor subfamily 1 group H member 4	Homo sapiens	135-155
18789348-5	2008	In this study, we report that CD suppresses in vitro reporter systems for human liver X receptors (LXRs) and activates those for human farnesoid X receptor (FXR), pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) in a concentration-dependent manner (0-50 muM).	Chlordecone	30-32	nuclear receptor subfamily 1 group H member 4	Homo sapiens	157-160
18789348-5	2008	In this study, we report that CD suppresses in vitro reporter systems for human liver X receptors (LXRs) and activates those for human farnesoid X receptor (FXR), pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) in a concentration-dependent manner (0-50 muM).	Chlordecone	30-32	nuclear receptor subfamily 1 group I member 2	Homo sapiens	163-182
18789348-5	2008	In this study, we report that CD suppresses in vitro reporter systems for human liver X receptors (LXRs) and activates those for human farnesoid X receptor (FXR), pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) in a concentration-dependent manner (0-50 muM).	Chlordecone	30-32	nuclear receptor subfamily 1 group I member 2	Homo sapiens	184-187
18789348-5	2008	In this study, we report that CD suppresses in vitro reporter systems for human liver X receptors (LXRs) and activates those for human farnesoid X receptor (FXR), pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) in a concentration-dependent manner (0-50 muM).	Chlordecone	30-32	estrogen receptor 1	Homo sapiens	193-216
18789348-5	2008	In this study, we report that CD suppresses in vitro reporter systems for human liver X receptors (LXRs) and activates those for human farnesoid X receptor (FXR), pregnane X receptor (PXR) and estrogen receptor alpha (ERalpha) in a concentration-dependent manner (0-50 muM).	Chlordecone	30-32	estrogen receptor 1	Homo sapiens	218-225
18789348-6	2008	Consistent with human PXR activation in vitro, three days after a single dose of CD (15 mg/kg) hepatic microsomal CYP3A11 protein increases in C57BL/6 mice.	Chlordecone	81-83	nuclear receptor subfamily 1 group I member 2	Homo sapiens	22-25
18789348-6	2008	Consistent with human PXR activation in vitro, three days after a single dose of CD (15 mg/kg) hepatic microsomal CYP3A11 protein increases in C57BL/6 mice.	Chlordecone	81-83	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	114-121
18789348-8	2008	Apolipoprotein A-I (apoA-I) contents of hepatic lipoprotein-rich and microsomal fractions of CD-treated mice are higher than controls.	Chlordecone	93-95	apolipoprotein A-I	Mus musculus	0-18
18789348-8	2008	Apolipoprotein A-I (apoA-I) contents of hepatic lipoprotein-rich and microsomal fractions of CD-treated mice are higher than controls.	Chlordecone	93-95	apolipoprotein A-I	Mus musculus	20-26
18387646-9	2008	Scavenger receptor class B type I (SR-BI) and ATP-binding cassette transporter G8 (ABCG8) proteins were quantified by western blotting in hepatic membranes from control and CD treated mice.	Chlordecone	173-175	ATP binding cassette subfamily G member 8	Mus musculus	83-88
17578864-4	2007	Both chlordecone and E2 activated splenic B cells and enhanced GC reactions, as shown by upregulated protein expression of GL7, CXCR5, and CXCR4.	Chlordecone	5-16	chemokine (C-X-C motif) receptor 5	Mus musculus	128-133
17996692-6	2007	Prolactin receptor in purified splenic B and CD4 T cells from treated animals, assessed through measurement of mRNA using quantitative real-time PCR, was increased by E2 treatment but unchanged in response to chlordecone.	Chlordecone	209-220	prolactin receptor	Mus musculus	0-18
17640991-6	2007	Here, we demonstrate that among three tested xenoestrogens, only kepone (>15-30 mg/kg) exerts sustained inductive response for uterine Bip expression.	Chlordecone	65-71	heat shock protein 5	Mus musculus	138-141
17640991-7	2007	Interestingly, this kepone-induced Bip strongly correlates with ERalpha-dependent growth and gene expressional responses in the mouse uterus.	Chlordecone	20-26	heat shock protein 5	Mus musculus	35-38
17640991-7	2007	Interestingly, this kepone-induced Bip strongly correlates with ERalpha-dependent growth and gene expressional responses in the mouse uterus.	Chlordecone	20-26	estrogen receptor 1 (alpha)	Mus musculus	64-71
17640991-9	2007	Although kepone at 7.5 mg/kg was not effective, it was strongly stimulatory by the adenovirus-driven forced expression of uterine Bip.	Chlordecone	9-15	heat shock protein 5	Mus musculus	130-133
17640991-11	2007	Furthermore, the induction of uterine Bip by stress-related signals also revealed the onset of uterine growth in mice when exposed to a sublethal dose of kepone.	Chlordecone	154-160	heat shock protein 5	Mus musculus	38-41
17578864-4	2007	Both chlordecone and E2 activated splenic B cells and enhanced GC reactions, as shown by upregulated protein expression of GL7, CXCR5, and CXCR4.	Chlordecone	5-16	chemokine (C-X-C motif) receptor 4	Mus musculus	139-144
17578864-6	2007	Chlordecone reduced total B cell and GC B-cell apoptosis without affecting proliferation, another feature shared by E2 treatment.	Chlordecone	0-11	natriuretic peptide receptor 2	Mus musculus	37-41
17578864-9	2007	Similarities in the effects of chlordecone and E2 on specific immune functions, such as diminished apoptosis in GC B cells, may provide valuable clues regarding key events in the acceleration of autoimmunity by E2, chlordecone, and other agents.	Chlordecone	31-42	natriuretic peptide receptor 2	Mus musculus	112-116
17578864-9	2007	Similarities in the effects of chlordecone and E2 on specific immune functions, such as diminished apoptosis in GC B cells, may provide valuable clues regarding key events in the acceleration of autoimmunity by E2, chlordecone, and other agents.	Chlordecone	215-226	natriuretic peptide receptor 2	Mus musculus	112-116
15253041-9	2004	Chlordecone, dicofol, methoxychlor, nitrofen, fenarimol, myclobutanil and pyridate had capacities to bind both ERalpha and AR.	Chlordecone	0-11	estrogen receptor 1	Homo sapiens	111-118
17088055-7	2006	Environmental estrogens with relatively high binding affinities for GPR30 (genestein, bisphenol A, nonylphenol and Kepone) also displayed estrogen agonist activities in an in vitro assay of membrane-bound adenylyl cyclase activity, a GPR30-dependent signaling pathway activated by estrogens.	Chlordecone	115-121	G protein-coupled estrogen receptor 1	Homo sapiens	68-73
17088055-7	2006	Environmental estrogens with relatively high binding affinities for GPR30 (genestein, bisphenol A, nonylphenol and Kepone) also displayed estrogen agonist activities in an in vitro assay of membrane-bound adenylyl cyclase activity, a GPR30-dependent signaling pathway activated by estrogens.	Chlordecone	115-121	G protein-coupled estrogen receptor 1	Homo sapiens	234-239
16626760-7	2006	Remarkably chlordecone and methoxychlor which were the most effective antagonist compounds for hERbeta, were agonists for hERalpha.	Chlordecone	11-22	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	122-130
15253041-10	2004	Chlordecone and pyridate were much more effective as competitors of estrogen binding to ERalpha than androgen binding to AR and, conversely, nitrofen was a more effective competitor of androgen binding to AR.	Chlordecone	0-11	estrogen receptor 1	Homo sapiens	88-95
16626760-6	2006	Antagonistic activities toward hERalpha and hERbeta were shown in three (carbaryl, pentachlorophenol and 2,4,5-trichlorophenoxyacetic acid) and seven (chlordecone, methoxychlor, carbaryl, endosulfan, endrin, dieldrin, aldrin) pesticides, respectively.	Chlordecone	151-162	estrogen receptor 1	Homo sapiens	31-51
15253041-9	2004	Chlordecone, dicofol, methoxychlor, nitrofen, fenarimol, myclobutanil and pyridate had capacities to bind both ERalpha and AR.	Chlordecone	0-11	androgen receptor	Homo sapiens	123-125
11695219-5	2001	E-cadherin protein levels decreased significantly by approximately 23% and approximately 69% following treatment with 0.1 and 1.0 microM Kepone, respectively, relative to solvent-treated cells.	Chlordecone	137-143	cadherin 1	Homo sapiens	0-10
9721260-7	1998	Administration of CLC resulted in increased CCl4-induced mortality from 25% to 85% in rats pretreated with CD, in contrast to 100% survival in ND rats.	Chlordecone	107-109	C-C motif chemokine ligand 4	Rattus norvegicus	44-48
9860886-5	1998	Previous studies from this laboratory have shown that nontoxic doses of chlordecone (10 ppm, 15 days) and carbon tetrachloride (CCl4) (100 microliters/kg) interact at the biologic interface, resulting in potentiated liver injury and 67-fold amplification of CCl4 lethality.	Chlordecone	72-83	C-C motif chemokine ligand 4	Homo sapiens	258-262
9721260-11	1998	In contrast, CLC administration to CD + CCl4-treated rats further delayed and diminished cell division by 80%, which led to unrestrained progression of CCl4-induced liver injury, resulting in 85% mortality.	Chlordecone	35-37	C-C motif chemokine ligand 4	Rattus norvegicus	152-156
10478865-4	1999	While 63-day-old females are more susceptible to the CD-CCl4 interaction than their male counterparts, the magnitude of the sex difference is diminished from that observed in 45-day-old rats.	Chlordecone	53-55	C-C motif chemokine ligand 4	Rattus norvegicus	56-60
10478865-6	1999	Hypotheses 33, 289-299) that chlordecone (CD) pretreatment eliminates the well-established sex difference in CCl4-treated rats.	Chlordecone	29-40	C-C motif chemokine ligand 4	Rattus norvegicus	109-113
10478865-6	1999	Hypotheses 33, 289-299) that chlordecone (CD) pretreatment eliminates the well-established sex difference in CCl4-treated rats.	Chlordecone	42-44	C-C motif chemokine ligand 4	Rattus norvegicus	109-113
9607801-12	1998	The heightened accumulation of LF mRNA in the epithelium in response to Kepone and o,p"-DDT was also severely compromised by pretreatment with ICI, but this antiestrogen had little effect on responses to p,p"-DDD.	Chlordecone	72-78	lactotransferrin	Mus musculus	31-33
9607801-13	1998	Similar to E2, Kepone increased the expression of PR mRNA in both uterine epithelium and stroma.	Chlordecone	15-21	progesterone receptor	Mus musculus	50-52
9371753-2	1997	By using ER-alpha "knock-out" (ERKO) mice, we demonstrate herein that a catecholestrogen, 4-hydroxyestradiol-17beta (4-OH-E2), and an environmental estrogen, chlordecone (kepone), up-regulate the uterine expression of an estrogen-responsive gene, lactoferrin (LF), independent of ER-alpha.	Chlordecone	158-169	estrogen receptor 1 (alpha)	Mus musculus	9-17
9371753-2	1997	By using ER-alpha "knock-out" (ERKO) mice, we demonstrate herein that a catecholestrogen, 4-hydroxyestradiol-17beta (4-OH-E2), and an environmental estrogen, chlordecone (kepone), up-regulate the uterine expression of an estrogen-responsive gene, lactoferrin (LF), independent of ER-alpha.	Chlordecone	158-169	lactotransferrin	Mus musculus	247-258
9371753-2	1997	By using ER-alpha "knock-out" (ERKO) mice, we demonstrate herein that a catecholestrogen, 4-hydroxyestradiol-17beta (4-OH-E2), and an environmental estrogen, chlordecone (kepone), up-regulate the uterine expression of an estrogen-responsive gene, lactoferrin (LF), independent of ER-alpha.	Chlordecone	158-169	lactotransferrin	Mus musculus	260-262
9371753-2	1997	By using ER-alpha "knock-out" (ERKO) mice, we demonstrate herein that a catecholestrogen, 4-hydroxyestradiol-17beta (4-OH-E2), and an environmental estrogen, chlordecone (kepone), up-regulate the uterine expression of an estrogen-responsive gene, lactoferrin (LF), independent of ER-alpha.	Chlordecone	158-169	estrogen receptor 1 (alpha)	Mus musculus	280-288